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ABSTRACT OF THE DISSERTATION
HIV-1 Sequence Analysis: Approaches and Applications from Transmission Network
Inference to Epitope Discovery
by
Nicolaus Lance Hepler
Doctor of Philosophy in Bioinformatics and Systems Biology
University of California, San Diego, 2019
Professor Sergei L. Kosakovsky Pond, Chair
Professor Douglas D. Richman, Co-Chair
Recent advances in sequencing technology, especially next-generation sequencing (NGS),
have become central to the study of rapidly evolving pathogens such as HIV-1. However, one
must contend with the massive amount of data produced by NGS as well as artifacts arising from
sample preparation and sequencing. To deal with these complexities, numerous bioinformatics
methods have appeared to enable researchers to extract the maximum value from their sequencing
data. Unfortunately, the number of methods and the difficulty of benchmarking have limited their
xv
reach; there is an opportunity for benchmarked, easy-to-use pipelines to increase the exposure and
use of more powerful techniques in lieu of naïve approaches. Here I present one such easy-to-use
pipeline for the analysis of NGS data, tailored to the analysis of HIV-1. I also present a method
for leveraging NGS data in the inference of molecular transmission networks, demonstrating
the increased power and resolution of these new technologies in revealing the central role of
dual infection in the HIV-1 transmission network. Finally, I present IDEPI–a framework for
the prediction of HIV-1 antibody epitopes from IC50-labeled env sequence data. IDEPI uses
predictive modeling to solve the general problem of inferring genotypic bases for phenotypic
characteristics, and is consequently also able to construct specialized genotype-to-phenotype
predictors, enabling computational surveillance applications. IDEPI demonstrates state-of-the-art
performance not just in HIV-1 antibody epitope prediction, but also in predicting HIV-1 co-
receptor usage (tropism), computational surveillance of drug resistance, and identifying signatures
of HIV-1 associated dementia.
xvi
Chapter 1
Introduction
1.1 A brief history of the HIV/AIDS epidemic
To understand the nature of the human immunodeficiency virus / acquired immunod-
eficiency syndrome (HIV/AIDS) epidemic and the sizable effort to control it, one must first
understand a few facts about HIV and some of its history. HIV is a retrovirus – a family of
enveloped single-stranded RNA viruses that store their genomes as mRNA, and include genes
for a reverse transcriptase (RT) and an integrase (int) to facilitate transforming their genomes
into DNA and integrating them into their host’s genome, respectively (Figure 1.1). HIV was
introduced into humans somewhere around the turn of the 20th century, in at least two zoonotic
events from chimpanzees/gorillas and sooty mangabey [130, 124]. These two events correspond
to HIV types 1 and 2, though HIV-1 makes the bulk of infections, and is the more pathogenic
strain.
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The identification of AIDS and the discovery of HIV as its causative agent took several
decades. The first documented cases of AIDS-related deaths go as far back as the late 1950s
[166, 156], but the virus was not identified until 1983 [7] and confirmed the following year [109].
The epidemic officially took hold in 1981, initially seeming to chiefly affect sexually active
homosexual men. This suggested sexual contact was a mode of transmission, and so the disease
was first called GRID, for gay-related immune deficiency, but the name was soon changed to
AIDS as the epidemic emerged in other groups.
We now know the phylogenetic provenance of HIV – it belongs to a family of lentiviruses
that has existed for at least 14 million years [39]. The simian immunodeficiency virus (SIV)
from which HIV evolved has existed for at least 32,000 years [157]. While SIV rarely develops
life-threatening complications in other primate species, in humans an untreated HIV-1 infection
typically develops into life-threatening AIDS within 10 years [83].
Given the eventual lethality of HIV-1 infection, treatments were desperately sought,
and the first was discovered in 1985 – azidothymidine (AZT), a nucleoside analog reverse-
transcriptase inhibitor (NRTI), which became the first FDA-approved treatment for HIV in 1987.
AZT targets the virus’s ability to synthesize DNA from its mRNA genome, halting HIV-1’s life
cycle. While potent, AZT is not completely effective – small amounts of the virus still replicate.
Consequently, after prolonged exposure to AZT, an HIV-1 infection will evolve resistance via
mutations to its reverse transcriptase [120]. Other drug treatments were discovered, and now drugs
are administered together in cocktails, known as highly active anti-retroviral therapy (HAART).
While the introduction of HAART has significantly reduced the number of AIDS-related deaths
2
in the developed world, it is neither uniformly effective nor widely available in the developing
world. Additionally, in order to effectively control an HIV-1 infection with HAART, a patient
must have regular exams to monitor their current regimen’s effectiveness, which will diminish
over time as the virus evolves resistance.
A vaccine, if available, would prevent new infections, halting the spread of the epidemic,
and would ideally prove curative for those already afflicted. While a vaccine development effort
has been in place for decades, no effective vaccine has yet been discovered. Chief among the
reasons for this failure is HIV-1’s ability to evade the host immune response. The adaptive immune
response, in the form of cytotoxic T-lymphocyte (CTL) recognition and antibody-producing
B lymphocytes, is rendered ineffective by HIV-1’s rapid mutation rate, said to approach the
mutational speed limit [162]. There is strong within-patient selective pressure on viral evolution
to evade the CTL response [134], and the rapid evolution of the envelope protein (env) makes
a consistent and potent antibody response almost impossible [68]. This evasion is so effective
that a preexisting HIV-1 infection is not guaranteed to prevent subsequent infections, a condition
known as super-infection [132]. Super-infection can provide additional viral diversity for the
infection to leverage via recombination, accelerating evolution, dampening the already ineffective
antibody response [95], and reducing the time till virologic failure [42].
HIV’s ability to evade the immune system, and the body’s inability to produce a protective
response to subsequent infections has obligated a different approach to vaccine design than we
employ, for instance, in developing the yearly influenza vaccine. The discovery of rare potent
broadly-neutralizing antibodies (bNabs) has suggested a vaccine targeted to specific epitopes in
3
env could yield an effective vaccine [11]. There is now an international effort to discover and
characterize bNabs to guide the design of an effective HIV-1 vaccine [146].
Until a vaccine has been developed, the public health community must rely on existing
treatments and epidemiology to devise strategies to slow or halt the spread of the epidemic.
Specifically, advances in sequencing technology have facilitated the implementation of molecular
epidemiology to the characterization of HIV-1 transmission networks [131]. HIV-1 transmission
propagates along sexual and social contact networks, with network structures belonging to the
scale-free family [59]. For scale-free networks with ρ < 3, no random intervention strategy
(e.g. "test and treat") will be capable of halting the spread of the epidemic regardless of its
transmissibility [59]. To emphasize the importance of this fact, a recent study of the HIV-1
epidemic in the UK estimated ρ to fall between 2 and 3 [74]. These revelations are driving the
development of targeted treatment strategies that promise a more effective means of controlling
the epidemic [77].
1.2 Sequencing advances and HIV-1 research
HIV-1 was first identified using manual Sanger sequencing of a clone taken from a patient,
a laborious process at odds with the natural diversity of an HIV-1 infection. Until recently, the
sequencing of patient samples was typically done with bulk PCR amplification from plasma and
Sanger sequencing, limiting the ability to resolve minor subpopulations. Studies requiring finer
resolution would resort to single genome amplification (SGA) and clonal sequencing, a process
costly in both time and resources. The advent of 2nd and 3rd generation sequencing technologies
4
(collectively “next-generation sequencing” or NGS) have promised greater resolution and lower
cost, but introduce problems with sample preparation, PCR artifacts, and sequencing artifacts; all
while requiring new tools to make sense of the data.
Here I propose an ultra-deep sequencing (UDS) pipeline for the analysis of NGS data
(Chapter 2). Additionally, I demonstrate the use of this pipeline for the enhanced inference of the
molecular transmission network of the San Diego Primary Infection Cohort (SD PIC) from avail-
able bulk and UDS data (Chapter 3). Finally, I describe a machine learning pipeline called IDEPI
(for IDentify EPItopes) originally designed to analyze clonal HIV-1 env sequences with matching
antibody in vitro titration data to predict HIV-1 antibody epitopes, along with extensions of this
pipeline to related applications in HIV-1 where predictive modeling of phenotypic characteristics
from genotypic data are useful, such as co-receptor tropism and drug resistance (Chapter 4).
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Figure 1.1: The genome arrangement of HIV-1.
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Chapter 2
A comprehensive, accurate, fast,
cross-platform and user-friendly pipeline
for the analysis of HIV-1 next-generation
sequencing data
2.0.1 Abstract
Next generation sequencing (NGS) is rapidly becoming the standard approach for charac-
terizing HIV-1 genotypic diversity. Despite several years of intense research activity, there is no
simple comprehensive informatics solution that is accessible to the average user on commonly
available hardware. We have developed such a solution, leveraging open-source software compo-
nents and algorithmic expertise from academic and commercial groups, for the analysis of HIV-1
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NGS data produced by any of the four commonly used platforms.
Because no single reference genome can be used for all HIV-1 samples, a sample-
specific reference (consensus) is reconstructed using the Quiver algorithm, developed by Pacific
Biosciences, which uses a hidden Markov model based approach to iteratively refine an initial
consensus generated by partial order alignment (POA). This algorithm is fast and achieves
accuracy greater than 99.99% on samples of known composition. Common sequencing errors
(e.g. spurious indels, homopolymer length miscalls, etc) are corrected using a codon-aware read-
mapping algorithm. Individual minority variants are called significant based on a multinomial
model.
We demonstrate the performance of the software on amplicon and whole-genome data sets,
generated using 454 FLX and PacBio RS II instruments. Importantly, our pipeline is engineered
to be easy to install, configure, and use: it does not depend on other complex software, such as
genome assemblers; it is provided under open-source licenses; and it is usable through a public
web-based interface (http://www.datamonkey.org).
2.0.2 Background
With the advent of next-generation sequencing (NGS) technologies, it is now feasible to
generate massive amounts of sequence data. Ultra-deep sequencing (UDS) projects in HIV-1
regularly utilize the Roche 454 Titanium FLX platform (hereafter just 454), which can generate
hundreds of thousands of individual reads. Other platforms include the Illumina MiSeq and Ion
Torrent Proton, which can each generate about 10 gigabases of data between about 50 million
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reads; and the Pacific Biosciences RS II, which can generate 70,000 reads with mean read lengths
greater than 10 kilobases.
These data have been used to study the evolution of drug resistance [147, 50], response
to host immune pressure [10, 55, 106, 80], tropism [4, 139], and acute infection [31]. A major
advantage of NGS platforms and UDS is the ability to detect low-frequency, or minority, genetic
variants. Given that circulating or archived minority variants associated with resistance HIV-1
treatments can lead to virologic failure [96, 72, 62], high-resolution characterization of minority
viral subpopulations is desirable. Bulk sequencing of patient plasma has been shown to be
ineffective at identifying minority variants with frequencies less than 10% [97], whereas NGS
platforms and UDS methodologies have recovered frequencies below 0.1% [161]. However,
care must be taken to distinguish real variation from artifacts of PCR and sequencing. PCR
mis-incorporation can introduce mutations at a rate of 10−4 to 10−5 [65], whereas sequencing
frequently introduces errors in low-complexity regions such as long homopolymers.
One approach to UDS has been to sequence clonal samples, but this is neither effective
in time nor resources. Given the errors introduced by PCR and sequencing are sample-specific,
it is necessary to derive error metrics from the sample. To facilitate this, we have developed a
suite of easy-to-use tools for filtering out low-quality data, mapping reads in a manner robust
to translation and downstream phylogenetic analysis, constructing a sample-specific consensus,
estimating error rates and removing statistically unsupported data from alignments, estimating
maximum divergence and site-wise selective pressure, as well as the identification of drug
resistance associated mutations.
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2.1 Methods and implementation
We have implemented a UDS pipeline for the analysis of HIV-1 data on the Datamonkey
webserver (http://www.datamonkey.org). Many of the individual components in the pipeline,
e.g. quality filtering and codon-aware alignment, are available at http://www.github.com/veg.
2.1.1 Quality filtering
“Garbage in, garbage out” is an old adage describing the expected results of analyzing
faulty data. UDS analysis in HIV-1 is no different, and we have implemented a quality filtering
tool, written in C++, called qfilt that can very rapidly cull low-quality regions from FASTQ
or paired FASTA and QUAL files. Sequences can be split or truncated when observing a user-
defined low-quality base (as observed in its PHRED score), optionally excepting low-quality
bases in homopolymers, whose lengths are frequently miscalled by the 454 instrument. We will
compensate for these errors downstream.
2.1.2 Codon-aware alignment and consensus estimation
As many of our downstream evolutionary analyses operate in codon space, we employ a
novel codon-aware alignment strategy first described by [47]. The user-chosen reference sequence
is assumed to be an open reading frame, and the recursive alignment algorithm includes 24 moves:
codon-match, -mismatch, -insert, -deletion, two-base match to a codon (3 moves), single-base
match to a codon (3 moves), 4-base match to a codon (4 moves), and 5-base match to a codon (10
moves, Figure 2.2). Scores for each of the moves can be based on an amino-acid score matrix (e.g.
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BLOSUM62) and codon translation table, or use a native codon score matrix [129]; the 1-, 2-, 4-,
and 5-base codon-match move scores are derived from this table with configurable penalties.
As the reference sequence is blessed with an open reading frame, and motion in the
reference is in complete codons only, only a third of the codon alignment dynamics programming
table needs be evaluated relative to a naiveë nucleotide alignment algorithm. This reduced search
space offsets the increased number of moves, and saves a constant factor of memory.
In the pipeline, users and upload their own reference sequence or use one or more
reference sequences we provide, including commonly-analyzed genes in HIV-1 such as gag,
pol, and env. When aligning against multiple references, each read will be aligned to each
reference, then grouped to the reference to which it has the maximum scoring alignment. In
addition, we estimate a sample-specific consensus for each reference group: reads are aligned
to the provided reference initially, then a sample-specific consensus is derived by employing
a sliding partial-order alignment (POA) approach to derive an initial consensus, which is then
subsequently refined using PacBio’s Quiver algorithm [16]. This approach is robust to in-del
polymorphism in quickly-evolving genes such as HIV-1’s env. Reads in each reference group are
then realigned to this sample-specific consensus. Alignments are provided in FASTA and BAM
format for easy downstream consumption, and graphs of coverage and majority proportion are
provided as a visual aid (e.g. Figure 2.1).
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2.1.3 Estimation of sequencing error
Downstream analyses (e.g. drug-resistance associated mutation identification) can be
confounded by the presence of sequencing errors, and conventional count- or percentage-based
approaches fail to take into account the coverage and distribution of observations at a site, and so
can lack stringency or power.
To get the most out of the data, we can determine if the observation of a character at a site
is above a target error rate r by sampling from the posterior of a joint multinomial mixture model.
At site i from an MSA, with an alphabet of M characters, the likelihood of observing counts of
each character ci, j for each site i and character indexed by j is given by
L(ci|p1) = n!
M
∏
j=1
pci, j1, j
ci, j!
(2.1)
where the parameters p1,1···M,∑Mj=1 p1, j = 1 are the multinomial event probabilities. Assuming
independence between sites, likelihood over all sites is given by
L(c|p1) =
s
∏
i=1
L(ci|p1) (2.2)
where s is the number of sites. Now consider a mixture model of K multinomial distributions
with parameters p1···K , the likelihood of the data under this model is given by
L(c|w, p) =
s
∏
i=1
K
∑
k=1
wkL(c|pk) (2.3)
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where wk,∑Kk=1 wk = 1 are the mixing weights. Rather than estimating the parameters w and
p directly, we employ a procedure like that in [89]. We specify a grid of p in advance, with
points placed about a target rate r and the log2 space between [0,1]. The conditional likelihoods
L(ci|pk) are computed for each site i over each set of multinomial event probabilities pk in the
grid. The distribution of weights is then sampled via the same efficient Markov Chain Monte
Carlo approach described in [89], yielding samples w[t]. By integrating over w[t], we can compute
the posterior probability that each count ci, j is at least above the target rate r. If the posterior
probability is beyond some threshold t, then it is reported as real.
2.1.4 Estimations of maximum divergence and selection
Identifying the presence of distinct viral subpopulations is one of the major advantages of
UDS over bulk sequencing, and in particular we can identify evidence of dual infection [131].
To estimate maximum divergence, we employ a sliding window approach with default width
and stride of 150 and 20 bases, respectively. When coverage across a given window exceeds
some predefined threshold (default 250), we identify all unique sequences with at least a fixed
number of copies (default 10) that completely span the window, compute all pairwise distances
between them using the TN93 distance metric [136], infer a phylogeny using the neighbor-joining
method [121], and estimate branch lengths by fitting the data to a general time-reversible model
of nucleotide evolution [138] using maximum likelihood. Statistical support is calculated by
bootstrapping (100 replicates), and maximum divergence is defined as the maximum path length
in the resulting tree. Assignment of multiple infection is determined by whether the maximum
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divergence exceeds some threshold (default 5%).
Estimates for diversifying and purifying selection are typically conditional on a known
phylogeny [24, 3]. However, given the limited length of 454 reads (< 500bp) and the low
diversity of patient samples (< 5%), phylogenies estimated from data have little statistical support.
Therefore, to estimate selection at a site we follow the procedure described in [66], considering
the ratio of expected non-synonymous and synonymous mutations assuming neutral evolution
given the genetic code and observed codon frequencies. We also compute the ratio of observed
non-synonymous to synonymous substitutions at a site by considering the mean numbers of non-
synonymous (n) and synonymous (s) substitutions along the shortest evolutionary path connecting
it to every other read (c−1 comparisons, for c reads at a site). Significance is assessed using the
binomial distribution, (
n+ s
s
)
ps(1− p)c−s, (2.4)
as the probability of observing s or fewer synonymous substitutions out of n+ s total substitutions
given an expected proportion (p) of synonymous substitutions given neutrality.
2.1.5 Identification of drug resistant variants
Common HIV-1 treatments target the reverse transcriptase, integrase, and protease. We
can screen UDS data of these genes for the presence of mutations that are known to confer
resistance to antiretroviral treatments, so called “drug resistance associated mutations” (DRAMs).
A comprehensive list of DRAMs is maintained at the Stanford HIV drug resistance database
(http://hivdb.stanford.edu) [118]. We rank the mutation rates for all sites, we can de-
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termine if the rank of a given DRAM site is significantly elevated by permutation test (1000
replicates). Elevation could signify the presence of selective forces acting preferentially on
DRAM sites. For additional corroborating evidence, we also characterize whether known com-
pensatory mutations occur more frequently with drug resistance mutations than expected by
chance using a Fisher exact test.
2.2 Results
To illustrate the pipeline, we present results derived from simulated 454 data (85,000
reads with lengths ~ Normal(500, 6400) [128]).
2.2.1 Alignment quality
Alignment quality was assessed from simulated 454 (clonal) data in two ways: first by
comparing the rates of non-synonymous mutations derived from a codon-aware alignment (using
the BLOSUM62 score matrix) to those derived from a naïve DNA-based alignment (using the
DNA65 score matrix), and second by similarly comparing the number of aberrant in-frame stop
codons. For these simulated data, codon-aware alignment had only a 0.016 non-synonymous
mutation rate, compared to 0.018 for DNA-based alignment, corresponding to an 11% reduction
in the number of non-synonymous errors. Similarly, the number of observed stop codons fell
from 3127 for DNA-based alignment to 622 for codon-aware alignment, an 80% reduction.
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2.2.2 Estimation of sequencing errors
On simulated 454 data containing both 1% and 10% minor subpopulations that differ at
18 sites, we were able to recover 100% of variants with a 14% FPR with a target rate of 1% and
posterior threshold of 95%, comparable to state-of-the-art techniques [8, 9, 149, 155, 82].
2.2.3 Application to global network inference
The codon-aware aligner was leveraged by Wertheim et al to infer the global tranmission
network of HIV-1 from every available HIV-1 group M pol sequence (N = 84,527, 1 sequence
per individual) [151]. These data represented 141 countries and contained 4342 connected
components with ≥ 2 nodes comprising 13,295 individual sequences. In particular, the (codon-
aware) alignment and subsequent pairwise comparison of 84,527 sequences using the TN93
evolutionary distance metric took < 8hrs on a 6 year old Apple laptop with a 2.53GHz Core 2
Duo, the latter being feasible because of the sensitivity of the aligner to codon similarity.
2.2.4 Application to intra-patient viral evolution
Near-full length env sequences (2.6 kb) were amplified from 3 samples from a single
patient at 3 months-, 22 months-, and 33 months-post the estimated date of infection. The circular
consensus sequences from these time points were aligned using the described pipeline, with
haplotype sequences inferred using hierarchical clustering of pairwise TN93 distances in tandem
with the consensus procedure described above. A phylogeny was created from the haplotypes
using neighbor-joining (Figure 2.3). Maximum divergence, diversity, synonymous and non-
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synonymous substitution rates, and the number of putative N-linked glycosylation sites were also
estimated (data not shown).
2.3 Conclusion
The analysis of UDS data from rapidly evolving organisms is a nontrivial task: one must
account for sequencing error, generate alignments, and perform other analyses specific to the
domain of interest. We have collected high-performance implementations of these processes,
including HIV-specific analyses, and provided them to users via a user-friendly interface on
http://www.datamonkey.org. The availability of pipelines such as this will facilitate more
rapid adoption of UDS, and broaden the use of best-practices, and help users the get the most out
of their UDS data no matter their preferred NGS technology.
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Figure 2.1: Site-specific coverage and majority proportion obtained from a single 454 UDS run
containing env (top), gag (middle), and rt (bottom) amplicons.
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Figure 2.2: An example of the recursive moves for codon-aware alignment: there are moves for
codon-(mis)match (M), -insertion (I), -deletion (D), single-base deletion (-1), double-base
deletion (-2), single-base insertion (+1), and double-base insertion (+2). Because the reference
sequence has a “blessed” reading frame, we only need to consider in 1/3rd the number of cells
(grey vs red boxes), for a space savings relative to naivë nucleotide alignment of 67%.
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Figure 2.3: A neighbor-joining phylogeny of viral haplotypes inferred from PacBio data
collected from a single patient across 3 time-points. Blue branches correspond to sequences
collected at the 3-month time-point, red branches to the 22-month time-point, and green
branches to the 33-month time-point; the size of the circular labels correspond to haplotype
frequency. Haplotypes were inferred by hierarchically clustering circular consensus sequences
and applying a partial order alignment consensus algorithm.
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Chapter 3
The central role of HIV-1 dual infection in
molecular transmission networks revealed
by next generation sequencing
3.1 Abstract
Objectives: Improve the resolution of molecular transmission network inference using
next generation sequencing (NGS) and characterize the placement of individuals dually infected
(DI) with subtype B viruses in the inferred network. Investigate whether targeting DI individuals
for treatment is beneficial to disrupting transmission.
Design: Longitudinal cohort study of individuals enrolled during primary infection.
Methods: Eligible individuals were cohort participants enrolled from December 1997
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to December 2012. We generated population-based (bulk) pol sequences (N = 921) from blood
samples for all participants (N = 648) and obtained NGS sequence libraries for a subset of partic-
ipants (N = 173). These data were used to establish genetic linkage between viral populations,
reconstruct a molecular transmission network, and examine the relationship between the DI status
of individuals and their placement in the network.
Results: Bioinformatics analyses of 634 NGS libraries representing 173 (26.7%) partic-
ipants added 33 genetic links to the molecular transmission network based on bulk sequences
alone. NGS analyses were shown to be reliable when replicated (3/4 replicates agreed on average),
and pol-based linkage was confirmed using env (82% cases) and gag (82% cases) sequences. The
NGS data tended to reveal missing connections in existing clusters rather than bridge clusters
(p < 0.01, permutation test [PT]), thus refining the network. DI nodes were centrally placed
(p < 0.001, PT) and densely connected (p= 0.04, PT) in the network, and NGS data were critical
for revealing this aspect. DI nodes were unusually interconnected (p < 0.001, PT), reinforcing
their role as network hubs.
Conclusions: NGS analyses can reveal phylogenetic links between minority viral sub-
populations, which is relevant in settings where dual infections are prevalent. The added links
improve the resolution of the transmission network. Individuals with intra-subtype DI exhibit
characteristics of network hubs and are good potential targets for treatment interventions to reduce
HIV-1 transmission.
23
3.2 Introduction
HIV-1 propagates along sexual and social contact networks, and the structure of the
network is largely responsible for the dynamics of disease spread [61]. HIV transmission
networks belong to the scale-free family, exemplified by small-world [148] and preferential
attachment [1] models. In these models, there are a small number of highly connected individuals,
or “hubs”, that substantially reduce the maximum path length between any two nodes in the
network. The structure of the transmission network has major implications for interrupting an
epidemic. In a scale-free infection network, a limited, randomly-applied intervention (e.g. HIV
“test and treat” strategy) will almost surely fail to disrupt network transmissions, since reducing
the basic reproductive number (R0) to below one requires eliminating a sufficient number of
hubs, who are crucial in the dissemination and maintenance of the epidemic [61, 74]. Moreover,
targeting prevention efforts at these hubs could greatly reduce prevention costs.
HIV-1 transmission networks are not observed directly, but rather are inferred and char-
acterized based on indirect measurements. Due to the chronic nature of infection and rapid and
host-specific evolution [112], HIV sequence isolates are essentially unique to each infected person.
This sequence uniqueness can be used to confirm or reject the hypothesis that two individuals are
linked by a recent transmission or belong to the same transmission cluster [125, 23]. Sequence
analyses have also clearly demonstrated the failure of interview data and contact tracing to estab-
lish HIV transmission history reliably. For example, in a highly monitored cohort of presumed
monogamous serodiscordant couples, up to 25% of new infections originated outside the rela-
tionship [29], whereas in cross-sectional studies this fraction often exceeds 50% [159, 117, 32].
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Phylogenetic [26] and phylodynamic [142] analyses developed in the past decade have made
it a more common practice to use HIV-1 sequence data for inferring and characterizing HIV-1
transmission networks [2, 36].
Most studies on HIV-1 transmission networks have relied on comparing population (bulk)
sequences from infected individuals, which can be thought of as “consensus” sequences. Thus,
a transmission link between two individuals is drawn if the corresponding bulk sequences are
genetically similar or form a strongly supported clade in a viral phylogeny. However, any of the
viral strains circulating in the source partner can be potentially transmitted to the recipient: for
example, transmission of low frequency drug resistant [33], “ancestral” [114] (though see [152]),
and HLA-mismatched escape strains [105, 85] have been reported previously. Additionally, it
has been shown that low frequency variants appear to be transmitted at higher rates than would
be expected by chance [63]. Using next generation sequencing (NGS) it is possible to better
characterize the intra-host viral population diversity and detect even low frequency transmitted
variants [147, 38]. This resolution is especially relevant given mounting evidence that dual
infection (DI), especially with viruses of the same subtype (intra-subtype), is relatively common
among MSM [133], including the SD PIC (intra-subtype B, 14.4%, 95% CI [8.6%–22.1%])
[95, 143], and in generalized epidemics [115]. HIV dual infection describes infection of the
host by two or more genetically distinct HIV-1 strains that likely originated from different
source partners, and which may be of the same subtype (intra-subtype) or different subtypes
(inter-subtype). Since these distinct viral populations circulate in the same host at varying levels,
methods that can extensively sample the viral population, like NGS, are needed to reliably identify
25
instances of DI [94].
In this study, we developed high-throughput bioinformatics techniques to infer putative
transmission links between minority viral populations and augment network inference with these
links. We also analyzed NGS data from longitudinally collected samples from SD PIC participants
to determine if such data could be useful to better resolve the transmission network, including
the placement of DI subjects, whom we hypothesize to be network hubs. We also performed
simulations to investigate whether or not preferentially treating DI subjects with antiretroviral
therapy could disrupt network transmissions more effectively than randomly targeting treatment.
3.3 Methods
3.3.1 Participants
The SD PIC, described in the supplementary information (Table S1) and in greater detail
elsewhere [95, 71], includes 648 individuals sampled between 1996 and 2012. For this study,
we used all of the available pol bulk sequences (N = 921) generated as a part of routine drug
resistance screening spanning all of protease and the first 330 amino acids of reverse transcriptase
(RT) (GenoSure, Monogram Biosciences).
3.3.2 Using NGS to define DI status
Dual infection status was determined by analyzing NGSdata (454 FLX Roche) from
HIV-1 env C2-V3, gag p24, and pol RT using a published bioinformatics protocol [95]. NGS
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libraries provided median coverage of 3100 reads / position in RT (IQR [1213–5663]), 3431 in
env (IQR [1458–5421]), and 7358 in gag (IQR [3520–11460]). Briefly, evidence of multiple
phylogenetically distinct viral populations in two or more independent NGS datasets was required
to call an individual DI. Individuals with DI were classified either as super-infected (SI) or
co-infected (CI), based on whether or not multiple viral populations were observed at baseline.
We studied 85 subjects screened as part of a separate study for which NGS data were available
(498 separate 454 libraries with multiple time-points and/or technical replicates per participant,
see Table S2).
3.3.3 Reconstructing the baseline (bulk) transmission network
We performed pairwise codon-corrected alignment of bulk pol sequences, following
previously published protocols [151], and computed all pairwise Tamura-Nei ’93 (TN93) [136]
nucleotide genetic distances, TN93(X,Y). Two individuals (A, B) were linked in the transmission
network if and only if the min TN93(X,Y) ≤ 1.5%, where X is an isolate from A and Y is an
isolate from B. A recent study of rates of longitudinal evolution in pol in San Diego showed that
this cutoff is a conservative bound for linking mono-infected subjects, even if the isolates are
taken several years following transmission, and that the choice of a particular genetic distance
does not significantly influence the outcome, if the sequences are closely related (1.5% or closer)
[48].
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3.3.4 Handling ambiguous bases
Presence of ambiguous nucleotide designations (e.g. Y or R) in bulk sequences often
reflects heterogeneous intra-host populations [105]. Our network construction algorithm based
on bulk sequences makes permissive links between sequences containing ambiguous bases (see
[2] for details): mixed bases are resolved so that TN93distance is minimized. Therefore, even
bulk sequences carry some information that makes it possible to link minority populations, but
this approach is limited both by poor sensitivity ( 20% [105]) and specificity (e.g. there are
210 = 1,024 such resolutions for a sequence with 10 2-way mixed bases, and it is unlikely that
most of them are actually present in the sample).
3.3.5 Establishing links between minority populations using NGS (and
bulk+NGS)
We used the sequenced pol reverse transcriptase (RT), (HXB2 coordinates 2708–3242)
from the 498 NGS libraries to establish linkage between minority populations. We further con-
firmed linkage with env C2-V3 (HXB2 coordinates 6928–7344) and gag p24 (HXB2 coordinates
1366–1619) amplicons, and studied the robustness of the method to experimental error by compar-
ing the results from multiple HXB2 libraries from the same individual/time-point when available.
The procedure for linking two RT NGS libraries sampled from individuals A and B, respectively,
is as follows:
1. Set L (linked count) to 0, and T (total count) to 0.
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2. For each quality-controlled and error-corrected [38] read X from A and Y from B, do:
(a) If the overlap between X and Y is fewer than 200 nucleotides, skip the pair; this step
guards against linking sequences based on regions that are too short to be informative;
(b) Increment T by 1, and if the TN93(X,Y) ≤ 1.5%, increment L by one.
3. If T ≥ 1,000 and LT ≥ 5%, report a link between A and B.
When the linked intra-host populations constitute the majority in both hosts (Figure 3.1A), then
the NGS procedure will simply confirm what bulk sequences can already detect. However, when
the link is between a majority and a minority population (i.e. at or below the sensitivity level
of mixed base sequencing; Figure 3.1B), then bulk sequence analysis is unlikely to detect the
connection, though the proportion of linked NGS reads remains high. Lastly, consider the case
when a 20% minority population is linked with a 30% minority population (Figure 3.1C); if 6%
of all pairwise comparisons reveal linkage then a connection will be drawn by an NGS analysis,
but this connection will almost surely be missed when comparing bulk sequences. The cutoff of
5% of all pairs requires that both linked populations are at least 5% frequent (e.g. 5% linked to
100%), and can be adjusted to balance sensitivity and specificity.
The procedure is implemented as an optimized C++ program (http://github.com/
veg/TN93) that can process a pair of NGS libraries with 10,000 reads each in less than a minute
on a multicore computer. Our approach does not reconstruct viral haplotypes (an open research
problem [128]), as would be required by a more traditional phylogenetic analysis, and it directly
incorporates allele frequencies, whereas typical phylogenetic methods do not [29].
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To guard against spurious linkage, we disallowed links between different subjects who
were sequenced in the same 16-way multiplexed assay (because there could be minor sample cross-
contamination between gasket-separated regions of the pico-titer plate). Finally, to compensate
for assay variability, when more than one replicate was available per individual/timepoint (Table
S2), we required that more that 50% of replicate-to-replicate comparisons supported the presence
of a link.
3.3.6 Characterizing global network properties
To quantify the changes in the transmission network due to the addition of NGS data,
we examined the number of connected individuals, the number of clusters, and the size of the
largest cluster. In order to understand which network formation process (e.g. random network
vs. a scale-free network) provides the best description of the SD PIC transmission network, we
followed previously published protocols [74]. Specifically, we fitted four parametric network
models (negative binomial, Pareto, Yule, and Waring) to the distribution of node degrees tabulated
from the SD PIC network using maximum likelihood and chose the best model using AIC. To
test whether or not the parameters of network models differed between bulk and bulk+NGS
networks, we used a likelihood ratio test; 95% confidence intervals of distribution parameters
were approximated with profile likelihoods.
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3.3.7 Network tests
We carried out Monte-Carlo and permutation tests to establish statistical significance.
Specifically:
1. To determine whether the increase in cluster number and maximum cluster size due to the
addition of X NGS links (edges) connecting Y nodes, of which P were newly added to
the network, we selected Y −P random nodes already in the bulk network, and P nodes
previously not connected to the network, and introduced X edges among this set of Y nodes
either randomly or using the process of preferential attachment [6]. We then computed
requisite statistics on N = 10,000 random networks to generate their null distributions and
derived p-values for the values observed in bulk+NGS network.
2. To assess whether a subset of nodes (S) in a network has atypically large or small values
for a particular measure (e.g. total degree, a measure previously shown to be a powerful
network-based statistic for evaluating prevention efficacy [150]), we performed permutation
tests, by selecting N = 10,000 random subsets Sr with the same number of nodes as S,
and computing the null distribution of the appropriate measure. Another version of this
permutation test (controlling for cluster membership) selects random subsets of nodes,
conditioned on the same number of nodes coming from a corresponding network cluster
(e.g. if 2 nodes in S came from cluster 1, and 3 from cluster 5, then each replicate will
have 2 random nodes from cluster 1 and 3 random nodes from cluster 5). For calculations
involving centrality, we employed the Floyd-Warshall algorithm to compute the average
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path length between every node s in S and every other node in the cluster containing s.
3. To estimate the efficacy of a hypothetical treatment (assumed to be 100% effective at
stopping onward transmission) applied to a subset of nodes (S), we performed network-
based simulations, following the protocol of [150]. Briefly, for each node X that receives
treatment we:
(a) Construct the neighborhood of C(X), (i.e. all nodes directly connected to X , or those
whose infection could have been prevented by treating X).
(b) For each node Y in C(X), we decide whether or not to remove Y from the network by
first counting the number of possible infection routes I(Y) for Y , estimated by the
count its inbound edges, plus half the count its undirected edges (see below), then
drawing a random number τ between 0 and 1, and checking if τ ≤ I(Y). For example,
if there is only one connection between X and Y , then Y will always be removed if
the edge points from X to Y , and will be removed with probability 50% if the edge is
undirected (because we cannot determine which partner is the source partner).
(c) Apply the same procedure recursively to each removed node.
A direction of each edge is determined based on the sampling date and the estimated date of
infection (EDI) [95]: whenever EDI of the “recipient” node was at least 30 days past the date at
which the “source” sequence was isolated. We conservatively assumed that chronically infected
subjects had an estimated duration of infection of at least 180 days. For each set of nodes S, we
ran N = 10,000 treatment simulations and recorded the total number of nodes removed from the
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network per node treated: a proxy for the number of prevented infections per index case.
3.4 Results
3.4.1 The SD PIC HIV-1 molecular transmission network
We reconstructed the bulk molecular transmission network from 921 population level pol
sequences, representing 648 cohort participants, and augmented it with 110 NGS-derived links
involving 104 individuals (Figure 3.2). With NGS, 77 (70%) of the links in the bulk network
were verified and 33 (30.0%) links were newly added (Table 1). When NGS data were included,
sixteen previously unconnected individuals were clustered in the network.
Consistent with previous reports for the UK [74] and world-wide [151] HIV-1 molecular
transmission networks, the degree distribution in the SD PIC network is best described by the
Waring model, suggesting that the governing process of network formation is a mixture of
preferential attachment and randomly drawn links; the network belongs to the scale-free family
[45]. The characteristic exponent of the network, ρ , is not significantly changed by the addition of
NGS-based links (Table 1, p > 0.1, LRT), confirming previous observations that global network
properties inferred from incomplete sequence data are fairly robust [151].
3.4.2 The effect of adding NGS data on transmission network properties
As might be expected, adding NGS-based links reduced the number of separate clusters
and increased the size of the largest cluster in the network (Fig 2). Surprisingly, the agglomeration
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of clusters by adding the NGS-based links was smaller than expected by chance. Specifically, a
random addition of 33 new edges between 104 nodes in the bulk network would be expected to
reduce the number of clusters to a median of 59 (IQR [57,61]), but 86 clusters were observed
(p < 0.001). Similarly, adding NGS-based links at random would be expected to increase the
maximum cluster size to a median of 186 nodes (IQR [175, 195]), but a maximum size of 64 nodes
was observed (p < 0.001). The same findings held, when random edges were added according to
a preferential attachment model: the number of observed clusters is greater than expected (median
67, IQR [65,69], p < 0.001); the largest cluster is smaller than expected (median 186, IQR
[177,194], p < 0.001). A likely explanation for this pattern is that NGS data could preferentially
fill in the connections in already existing clusters, rather than bridging previously disconnected
clusters. Indeed, the bulk+NGS network has significantly shorter mean path lengths between
clusters with 5 or more members (p < 0.01 after adjusting for cluster sizes) than the network built
with bulk sequences alone (i.e. bulk network). Thus, NGS data primarily increase the connectivity
in existing clusters rather than expanding the diameter of the network.
3.4.3 The placement of DI individuals in the transmission network
We sought to test our hypothesis that dually infected individuals are hubs in the inferred
molecular transmission network: they should be involved in more transmission events, on average,
than are mono-infected individuals and should be more centrally located in the transmission
network. Of the 16 individuals with DI, 11 were in the connected components of the bulk+NGS
network (6 superinfected, 5 coinfected; [95]; Figure 3.2). These 10 DI nodes were:
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1. Unusually connected: the total degree (72) of the DI nodes was significantly greater than
expected by chance (median 31, IQR [24,39]; p = 0.02, PT). This difference remained
when random edges were added according to the cluster membership of the DI nodes
(p = 0.07).
2. Unusually interconnected: there were 5 network edges connecting DI nodes directly,
compared to a median of 0 (IQR [0,1]) for a random subset of 10 nodes (p < 0.001,
PT). This difference remained significant even when corrected for cluster membership
(p = 0.03).
3. Unusually central: the 10 DI nodes connected in the network had significantly shorter
(p = 0.01, rank-sum permutation test) mean path lengths to other cluster members (i.e.
they are cluster hubs), compared to random subsets of 10 nodes corrected for cluster
membership.
3.4.4 The potential of DI individuals as intervention targets
Given that DI nodes play an unusually central role in the HIV-1 transmission network, we
investigated how efficacious targeting this subset of individuals for antiretroviral therapy (ART)
might be, when it is assumed to prevent 100% of onward transmissions. To this end, we exploited
estimated durations of infection and sampling dates to assign directions to a subset of transmission
edges (Figure 3.2), and the fact that the SD PIC network spans over 15 years of data, to estimate
how many infections might have been prevented by targeting the DI individuals. Targeting the 11
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connected DI individuals (Figure 3.2) with ART was predicted to prevent a median of 16 (IQR
[12,20]) HIV-1 infections in the community (1.5 prevented infections per treated individual).
This outcome is better than 95% of simulations in which 11 random connected individuals were
treated, preventing a median of 9 infections from the community (0.9 infections per treated
individual). The improved efficacy of treating individuals with DI versus treating a randomly
selected pool of individuals is apparent (Figure 3.3), as removing DI individuals as potential
sources of transmission has cascading effects and disrupts many pathways for transmission in
the network. The potential importance of targeting DI nodes for prevention is revealed using
NGS data; without the additional links provided by NGS data, the estimated efficacy of treating
DI nodes drops to 1.2 per case, which is not substantially better than treating randomly selected
nodes.
3.5 Conclusions
With the increasing implementation of HIV-1 molecular epidemiology [75], NGS data
will most likely become the primary source of information for deducing the structure of pathogen
transmission networks. In this paper we present a simple, fast, and powerful bioinformatics
approach to harness the rich information about intra-host HIV population diversity contained
in NGS samples. We show that bulk sequencing–still the most common source for molecular
transmission network inference often fails to find links between minority intra-host viral popu-
lations. Armed with the additional resolution afforded by NGS data, we studied a particularly
important subset of HIV-infected individuals: those with dual infection (DI) (i.e. those infected
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with multiple HIV strains). Because individuals with DI harbor diverse viral populations [95],
adding NGS data to network inference will significantly increase our ability to quantify the
connectivity and centrality of these DI individuals in the local network. Indeed, our analyses
revealed with multiple independent measures that DI nodes were hubs in the SD PIC transmission
network: they had significantly more links than other nodes, showed a remarkable degree of
interconnectedness, and resided in central locations in the network. Further, we propose that
based on their connectedness in the network and the results from our simulations, identifying
DI individuals and treating them with suppressive ART may be a promising strategy to reduce
population-level incidence [150, 28].
Our study has a number of limitations. First, not all individuals in the SD PIC have been
characterized for DI status, and our DI determination algorithm is conservative, meaning that
some mono-infected individuals could have been dually infected. Second, our NGS linkage
protocol could still miss connections between minority populations, assuming they are at a
frequency too low to pass the 5% cutoff. Additionally, the molecular transmission network
inferred from SD PIC data is incomplete, due to the lack of exhaustive sampling of the local
epidemic, and not necessarily free of spurious links, although we devised statistical testing to be
robust against network reconstruction error (e.g. by deriving null distributions conditioned on the
network topology, see Wertheim2011ab for more details). Finally, DI determination requiring
NGS data might also be seen as a limitation, but the relevance of this restriction will diminish as
NGS technologies become standard.
Despite these limitations, our results establish the importance of studying DI for its
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potential importance in population level spread of HIV-1 [42, 43, 95]. Further work is required,
however, to understand the behavioral, clinical, or viral determinants for the hub property of
DI nodes. A parsimonious explanation would be that DI is at least partly a consequence of the
central location in the transmission network, which could indicate more contacts, higher risk of
transmission per contact, or a membership in a rapidly expanding transmission cluster. We also
not that the majority of characterized DI cases in SD PIC occur in the first year of infection [48],
when the risk for transmission is higher than in later years. However, other factors, such as viral
and host genotypes [18, 144, 64], dynamics of the immune response [95, 21], and co-infections
[76] likely contribute to the incidence of DI, and as more cases of DI are identified and studied,
the relative contributions of these factors will become better characterized.
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3.7 Figures
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Figure 3.1: Examples of intra-host population compositions that would be detected by our
NGS-based analysis. Black represents subpopulations within 1.5% TN93 distance of each other
(linked); while other shades of gray represent subpopulations more than 1.5% TN93 distant
(unlinked).
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Coinfection Superinfection
Bulk (487) NGS verified (53) NGS added (58)
Figure 3.2: The connected components of the molecular transmission network for the San
Diego Primary Infection Cohort (SD PIC). Edges are shaded according to their provenance:
bulk only (no corresponding NGS data), bulk+NGS (NGS verified), and only NGS (NGS
added). Edge direction is established, whenever possible, using EDI and sampling data (see
methods). Note that edge direction does not imply direct transmission, but is instead
exclusionary (transmission could not have occurred in the opposite direction). The color of a
node denotes its dual infection status, determined using an NGS-based phylogenetic screening
described previously [95].
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Figure 3.3: Simulated effects of administering a treatment 100% effective at preventing onward
transmission to 0 dually infected nodes in the connected components of San Diego Primary
Infection Cohort (SD PIC) (left) or 10 randomly chosen nodes in the connected component of
the SD PIC (right).
42
3.8 Tables
Table 3.1: San Diego Primary Infection Cohort molecular transmission network properties (N = 648)
1 A total of 921 bulk sequences representing 648 individuals were available to build the network.
2 NGS data were available for 173 individuals.
Property Bulk sequences only1 Bulk sequences + NGS data2
Number of connected nodes (%) 339 (52.3%) 355 (54.8%)
Number of edges 540 573
Number of clusters 90 86
Largest cluster size 62 94
Characteristic exponent Waring dis-
tribution, ρ (95% CI)
3.61 (3.16–4.14) 3.78 (3.32–4.33)
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Chapter 4
IDEPI: rapid prediction of HIV-1 antibody
epitopes and other phenotypic features
from sequence data using a flexible
machine learning platform
4.1 Abstract
Since its identification in 1983, HIV-1 has been the focus of a research effort unprece-
dented in scope and difficulty, whose ultimate goals — a cure and a vaccine – remain elusive.
One of the fundamental challenges in accomplishing these goals is the tremendous genetic vari-
ability of the virus, with some genes differing at as many as 40% of nucleotide positions among
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circulating strains. Because of this, the genetic bases of many viral phenotypes, most notably the
susceptibility to neutralization by a particular antibody, are difficult to identify computationally.
Drawing upon open-source general-purpose machine learning algorithms and libraries, we have
developed a software package IDEPI (IDentify EPItopes) for learning genotype-to-phenotype
predictive models from sequences with known phenotypes. IDEPI can apply learned models to
classify sequences of unknown phenotypes, and also identify specific sequence features which
contribute to a particular phenotype. We demonstrate that IDEPI achieves performance similar to
or better than that of previously published approaches on four well-studied problems: finding the
epitopes of broadly neutralizing antibodies (bNab), determining coreceptor tropism of the virus,
identifying compartment-specific genetic signatures of the virus, and deducing drug-resistance as-
sociated mutations. The cross-platform Python source code (released under the GPL 3.0 license),
documentation, issue tracking, and a pre-configured virtual machine for IDEPI can be found at
https://github.com/veg/idepi.
4.2 Introduction
The challenge of predicting a viral phenotype from sequence data has many motivating
examples in HIV-1 research. In this work we restrict our attention to predicting binary phenotypes,
e.g. resistant vs susceptible, although IDEPI can be extended to predict continuous phenotypes
as well. Perhaps the most established application is that of determining whether or not the viral
population in a particular host harbors drug resistance associated mutations (DRAMs)[137].
Algorithms for inferring this from viral genotype alone (e.g. [79]) are well established and
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used both in research[107] and in clinical practice [49]. These algorithms have been developed
based on large training sets using phenotypic assays, for example those measuring half maximal
inhibitory concentration (IC50) of an antiretroviral drug (ARV) [164] to label sequences resistant
or susceptible. For many ARVs, the genetic basis of resistance is simple and consists of specific
point mutations [137]. This makes it possible to distinguish resistant viruses from their susceptible
counterparts by the presence or absence of a specific residue or a set of residues, leading to reliable
prediction [35, 58]. For other ARVs, including some protease, integrase, nucleoside reverse
transcriptase inhibitors, and co-receptor antagonists, the resistance phenotype is determined by
the interaction of many sites [108, 119, 86, 37, 140], or the protein tertiary structure [163, 160],
prompting ongoing methodological development (e.g. [111, 46, 57]).
Another popular prediction problem is that of determining which of the two cellular
co-receptors needed for HIV-1 fusion with (and infection of) the target cell can be used by a
particular viral strain. The ability of a virus to bind CCR5 (R5-tropic), CXCR4 (X4-tropic), or
either (dual-tropic) determines the efficiency with which it can infect different types of target
cells [87], predicts whether or not certain ARVs will be effective [141], and impacts the course
of disease progression [100]. The primary determinant of co-receptor usage is thought to be the
third variable loop (V3) of the envelope glycoprotein (env) [22], which spans approximately 35
amino-acid residues. Specialized assays can be used to determine the tropism of a virus with
a particular env protein [154], providing both the training sets and the gold standard against
which computational prediction methods can be compared [122, 110]. Starting with the work
by Fouchier and colleagues in 1992 [34], which used the computed total charge of V3 to derive
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and experimentally validate the simple 11/25 rule (if residues at sites 11 and 25 are positively
charged, then the virus is classified as X4 tropic), numerous authors have applied decision trees
[101], random forests [27], position-specific scoring matrices [56], support vector machines
(SVM) [101], neural networks [116], Bayesian networks [25], and hybrid models [67] to the
problem. Various feature engineering approaches including using structural information[123],
electrostatic hulls [27], sequence motifs [56], and positional and segment residue frequencies [67]
have also been attempted. At present the best methods achieve accuracy on the order of 85% on
comprehensive training datasets, thereby justifying ongoing research to improve this value [81].
A different class of prediction problems arises naturally when researchers seek to infer
genetic “signatures” of HIV-1 isolates from different anatomical compartments (e.g. blood vs
cerebro-spinal fluid [102]), individuals with different clinical attributes (e.g. those with and
without neurocognitive impairment [51]), and different disease stages (e.g. acute vs chronic
infection [40]). Once again, the interest is both in prediction for unlabeled sequences, for example
to modify treatment before impairment occurs [51], and in finding predictive features, for instance
to target vaccine research towards HIV-1 strains that are more likely to establish new infections
[40].
One of the most promising avenues of HIV-1 vaccine research provides our final example
of genotype to phenotype association problems, and the one that IDEPI was specifically developed
to address. Rational HIV-1 vaccine design has been greatly advanced by the isolation and
identification of broadly neutralizing antibodies (bNab), typically from chronically infected
individuals [13]. By definition, a bNab is able to neutralize (in experimental assays) a large
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proportion of reference viruses (e.g. [146, 165, 145]). Understanding which epitopes are being
targeted can reveal “conserved” elements shared by many circulating viruses, and help design
a vaccine which elicits responses to the same epitopes [11]. While powerful and illuminating,
current biochemical and structural techniques for mapping bNab epitopes (e.g. [165, 145, 98]),
are expensive, time consuming, and do not necessarily lead to good predictive models (e.g. [93]).
The appeal of computational epitope prediction lies in generating hypotheses for experimental
validation and in high-throughput screening of sequences with unknown resistance phenotypes.
As a byproduct of bNab characterization, large panels of phenotypic (IC50) and matched envelope
sequences have been generated, and several recent efforts [41, 153, 17, 30, 70] have been directed
at applying machine learning techniques to these data in order to predict the resistance phenotypes
of HIV-1 strains and to infer antibody epitopes.
To provide a unified solution for these and similar problems, we designed IDEPI – a
domain-specific and extensible software library for supervised learning of models that relate
genotype to phenotype for HIV-1 and other organisms. IDEPI makes use of open source li-
braries for machine learning (scikit-learn, scikit-learn.org/), sequence alignment (HMMER,
hmmer.janelia.org/), sequence manipulation (BioPython, biopython.org), and paralleliza-
tion (joblib, pythonhosted.org/joblib), and provides a programming interface which allows
users to engineer sequence features and select machine learning algorithms appropriate for their
application.
IDEPI is powerful and accurate: when we compare its performance with that of special-
ized tools on the four classes of problems outlined above, we find that even without feature and
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machine learning method tuning, IDEPI closely hews to or even outperforms existing methods on
the same data. IDEPI infers biologically meaningful features: for each studied problem IDEPI
identified many or most of the genetic sequence features that have been previously shown to affect
phenotype. IDEPI is convenient: by standardizing data manipulation, e.g. aligning sequences to
standard reference coordinates, extracting features to be modeled, reading and handling phenotype
annotation, and providing means to save learned models and easily reuse them later, IDEPI can
empower researchers interested in tackling new problems to focus on innovation, instead of rote
utility software development; IDEPI makes tasks like retraining a classifier on different data
sets trivial – something that is difficult to impossible to do with many published algorithms.
IDEPI is fast: automatic parallelization of independent tasks (e.g. cross-validation) on multi-core
architectures greatly accelerates model learning and performance evaluation; for the default
linear support vector machine (LSVM) classifier, classification of new sequences given a model
can be done at a rate of 104−105 sequences per minute, making the program suitable for the
analysis of next generation sequencing data. IDEPI is customizable: different machine learning
algorithms implemented in scikit-learn can be used; new sequence features can be defined using
a well-specified application programming interface (API); various feature selection approaches
(e.g. forward or backward selection) can be used; performance can be optimized with respect to
many metrics (e.g. sensitivity).
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4.3 Design and Implementation
4.3.1 IDEPI architecture and dependencies
IDEPI is implemented in the Python 3 programming language and leverages open-source
and community-developed libraries to implement reusable functionality: BioPython for biological
sequence data structures and for parsers of FASTA- and Stockholm-format files; NumPy (numpy.
org) and SciPy (scipy.org) for vector, matrix, and other common numerical recipes; and
scikit-learn (scikit-learn.org) for various machine-learning algorithms. When extending
the facilities provided by these libraries, IDEPI provides compatible application programming
interfaces so that its components are reusable and similarly extensible.
IDEPI accepts two forms of input data – a specially-crafted SQLite database (sqlite.org)
or a combination of FASTA-formatted sequences with supplemental phenotypic data in comma-
separated value (CSV) format (see Figure 4.1). These input data are transformed by IDEPI into
a multiple sequence alignment (MSA) using HMMER (version 3.1b1). Because the authors of
HMMER recommend providing amino-acid sequences to the program, IDEPI will by default
translate the input sequences if they are determined to have a DNA alphabet. A user-provided
reference multiple sequence alignment (MSA) is modeled by HMMER to guide an iterative
construction of an MSA from the input data. IDEPI can also be instructed to treat the input
MSA is fixed if automated alignment is not desired (e.g. for difficult to align sequence regions).
Additionally, IDEPI includes a user-provided reference sequence in the alignment to label the
columns of the MSA in a conventional manner (e.g. N332 for an asparagine at site 332). IDEPI
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distribution includes the standard HXB2 (genbank accession number K03455) reference sequence
for assigning HIV-1 coordinates.
4.3.2 Feature extraction techniques included with IDEPI
For feature extraction, IDEPI provides four classes (all scikit-learn compatible) for the
vectorization of labeled MSAs.
1. Presence of a particular residue at a given site (e.g. N301N); optionally a match is returned
if the residue belongs to a predefined class of biochemically similar residues, e.g. using
Stanfel encoding, N301[DENQ] [135]. IDEPI can generate either aminoacid or nucleotide
sequence features, with the preference specified as a command line argument (encoding).
2. Presence of a pair of specific residues at two sites, e.g. N301N+S334S, also optionally
supporting class membership. To limit the number of all pairwise combinations IDEPI only
considers pairs of sites that are no more than D (a user-tunable parameter) positions apart
in the linear sequence.
3. Presence of a sequence motif defined by a regular expression, e.g. potential N-linked
glycosylation sites (PNGS), using the regular expression “N[ˆP][TS][ˆP]”.
4. Presence of a sequence motifs defined by the same regular expression at two sites at once,
e.g. PNGS (N234+N276).
For label extraction, IDEPI provides a class which converts phenotype data to a form
usable by scikit-learn.
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4.3.3 Feature selection and learning algorithms used by IDEPI
To enable rapid learning and prevent overfitting, IDEPI performs feature selection using
the minimum redundancy maximum relevance (mRMR) algorithm [99]. Briefly, the algorithm
chooses features sequentially (the greedy approach), in way to maximize the mutual information
with the label and minimize mutual information with already-chosen features. Sets of strongly
correlated features will be typically represented by single member in the model selection process.
IDEPI provides a mechanism to report all “similar” features, so that possible biological features
are not masked by accidental correlates. mRMR is implemented in the separate sklmrmr package,
also scikit-learn compatible, and uses Cython (cython.org) for high performance.
Default model learning is implemented using a soft-margin, linear support vector machine.
The soft-margin parameter, C, is chosen by (inner) grid search to maximize a performance metric
chosen by the user (Matthews Correlation Coefficient is the default). Both of these functions are
implemented within scikit-learn, and parallelized when possible.
4.3.4 Tools included with IDEPI
IDEPI provides three scripts for end users not wishing to directly program their own
pipelines.
1. idepi discrete accepts labeled sequence data and will generate an MSA from these data,
extract features and labels, perform N-fold cross-validation on models built from a pipeline
of mRMR and soft-margin linear SVMs, and finally report the models’ performance along
with the labels of the most frequently selected features and their relationship to the models
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(e.g. is the presence or absence of the feature indicative of an outcome).
2. idepi learn will similarly accept labeled sequence data, learn a model, and save it to
disk for later use.
3. idepi predict accepts a saved model and some unlabeled sequences (homologous to the
model) and will predict their labels.
All the results presented in the manuscript have been generated using these three scripts,
and detailed tutorials are available at http://github.com/veg/idepi.
4.3.5 Extensible API for feature engineering
IDEPI defines a LabeledMSA class as a wrapper around BioPython’s MultipleSeqAlign-
ment for the column-wise labeling of an MSA. Together with classes facilitating alphabet encod-
ing, IDEPI provides simple facilities enabling rapid feature engineering for biological sequence
data. Examples of how these facilities can be used can be found within IDEPI’s source code –
the SiteVectorizer and MotifVectorizer classes for feature extraction. Additionally, motif
features are trivially supported by the MotifVectorizer class, which accepts a regular expres-
sion argument describing the motif. IDEPI uses this functionality to extract features for potential
N-linked glycosylation sites (PNGS), using the regular expression described above.
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4.4 Results
We first tested IDEPI on simulated data and on well-studied problems of drug-resistance
and tropism prediction and detection of tropism-associated genetic features. The large number of
published methods make a comprehensive comparison infeasible, hence we selected methods
based on their popularity, recency, performance, and the availability of training data. IDEPI was
evaluated for (i) its performance in phenotype prediction using standard cross-validation metrics
and on previously published independent datasets; and (ii) the veracity of the genetic features
inferred to be informative of a particular phenotype. All the datasets and instructions needed to
run them with IDEPI are provided with the package distribution.
4.4.1 Simulated data
In order to establish baseline performance of IDEPI where the true “phenotype” is known,
we simulated the evolution of N = 241 HIV-1 protein envelope sequences subject to directional
selective pressure applied to sites in an epitope along a subset of terminal tree branches selected
at random. For this moderate size data set (chosen to represent a typical bNab training set),
IDEPI performs very well overall (Table 4.1), both in terms of classification performance and in
recovering the locations/residue identity of epitopes. In the simplest case, when any mutation in a
5-site epitope confers resistance, IDEPI delivers a Matthews Correlation Coefficient (MCC) of
0.98 (MCC of 1 indicates a perfect classifier, and MCC of 0 corresponds to “no-better than random
prediction” performance), and recovers > 50% of sites within epitopes if they are sufficiently
variable. Because positions in epitopes are likely quite correlated, mRMR redundant feature
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selection captures essentially all of the signal with a median of 2 features per replicate. For a fixed
training data set size, with the increased epitope length and complexity, the performance degrades
predictably, but MCC remains excellent for intermediate (8 sites and 2 or more mutations needed
for escape) epitope complexity (0.94) and good (0.78) for high (10 sites and 3 or more mutations
needed for escape) epitope complexity. Encouragingly there seems no false association signal due
to the phylogenetic relatedness of the samples: IDEPI yields a median MCC of 0.04 for randomly
assigned phenotypes, which is essentially the same as a random prediction (also see discussion of
the 2F5 bNab below).
4.4.2 Drug resistance
We used a large publicly available data set of viral sequences (reverse transcriptase) and
matched IC50 values for the PhenoSense assay (available from the Stanford HIV Drug Resistance
Database, hivdb.stanford.edu) to train an IDEPI classifier for resistance to a non-nucleoside
reverse transcriptase inhibitor nevirapine (NVP). We chose this drug as a test case because (i)
the basis for its resistance is well understood, making the assessment of IDEPI predictions
easy; (ii) testing for NVP resistance is biomedically relevant, for example in the context of
preventing mother to child HIV-1 transmission; (iii) a recent study [113] used resistance data
from the Stanford database to train specialized classifiers for NVP resistance, providing a basis
for comparison.
With 80 features (the number selected by a grid search, see Figure 4.2.A), IDEPI achieves
the same accuracy (0.92, Table 4.2) as a state-of-the-art custom-built prediction tool using struc-
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tural information [113]. The first three selected features (K103K, Y181Y, G190G, see Table 4.3),
correspond to three canonical sites of strong phenotypic resistance, and the maintenance of the
wildtype residue at each of the positions is strongly predictive of susceptibility – a classifier built
on just these three features achieves an MCC of 0.74, compared to that of 0.83 for the 80-feature
model. Other genetic features implicated in the development of NVP resistance recovered by
the IDEPI model include major resistance mutations K101P, K103N, V106A, Y181C, Y188L,
G190A, and accessory/weak resistance mutations L100I, E138Q, H221Y, and V108V, P236P
(the latter two associated with susceptibly)[137]. Note that the same site can appear in multiple
features (e.g. Y181Y as a feature of susceptibility and Y181C – as a feature of resistance), hence
an 80-feature model does not span 80 different sites of HIV-1 reverse transcriptase.
We compared the SVM model learned by IDEPI against perhaps the most commonly used
drug resistance prediction algorithm – the Stanford HIVdb (expert curated, and evidence based)
[79], using a large dataset collected in Mexico for the purposes of drug resistance surveillance
[5]. Because no phenotype measurements were available for these sequences (as is common in
practice), we computed the degree of concordance between IDEPI and HIVdb using Cohen’s κ
[19]. Since HIV-1 pol sequences obtained during routine surveillance are amplified from mixed
viral populations and often contain ambiguous bases, not directly handled by default IDEPI
feature sets, we considered all possible amino-acid resolutions of nucleotide level ambiguities
at the positions involved in the model, and called a sequence resistant if any of the resolutions
were predicted as resistant. The two methods of resistance prediction were in excellent agreement
overall (κ = 0.85), including all cases of “highly-resistant” sequences. This is on par with the
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numbers reported in a recent comparison of several rule-based resistance prediction algorithms
[78].
4.4.3 Co-receptor usage/tropism
In 2010, Dybowski et al [27] presented a sophisticated multi-level classifier including
structural and biochemical properties of the V3 loop, performed extensive training and validation
of their approach, and compared it to previous work. Because a large training data set of V3 amino-
acid sequences and associated phenotypic measurements was provided as a part of the publication,
we were able to train an IDEPI classifier on the same data to enable a direct comparison.
As has been documented before (e.g. [27]), most of the predictive power of V3 sequences
is captured by only a few features – in the case of IDEPI, a model using only two features already
achieves an MCC of 0.67, while the full model with 90 features improves it to 0.78. The first
selected feature is a potential N-linked glycosylation site (PNGS) at position 301; several sites in
this 4-residue motif have been implicated as critical to CCR5 receptor binding [20], hence a single
composite feature is able to encapsulate the discriminating positions for many sequences. The
second feature is one of the two residues in the 11/25 rule [34]; interestingly, the two positions are
sufficiently correlated in the training sample that mRMR feature selection eliminates position 25
once 11 has been included. IDEPI appears to be surprisingly well suited to the problem of tropism
prediction, and delivers nearly the same accuracy (0.94 vs 0.96, the latter number obtained in the
original publication by tuning algorithmic cutoffs to maximize accuracy on the training data) as
the much more complex feature engineering approach undertaken by Dybowski and colleagues.
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Furthermore, on an independent dataset, IDEPI attains accuracy of 0.905, whereas the best of the
5 methods compared previously [27] attained accuracy of 0.86.
4.4.4 HIV-1 associated dementia
A recent comprehensive study by Holman and Gabuzda [51] applied a machine learning
pipeline (based on decision trees) to partial envelope sequences to identify signatures (defined
as collections of residues or biochemical properties at specific genomic positions) of sequences
isolated from brain tissue of subjects who developed HIV-1 associated dementia (HAD). Since
the training set of sequences and corresponding diagnoses has been kindly made available by the
authors through the HIV Brain Sequence Database [52], it was straightforward to apply IDEPI to
the same data to learn a classifier. The Holman and Gabuzda study also included an independent
validation data set of 10 individuals diagnosed with HAD, and we used it here to test the learned
model.
IDEPI excels at this classification problem, with both specificity and sensitivity exceeding
0.9, and achieving an accuracy of 0.95. The original authors reported an accuracy of 0.75, but
their model was restricted to a subset of the available sequence length, HXB2 env amino-acid
coordinates 265-369. When restricted to the same subset of residues, IDEPI achieves an accuracy
of 0.96 with 100 features (detailed results not shown), suggesting that many of the predictive
features are correlated (and mRMR selects only one), because the performance does not degrade
when only partial sequences are considered. As with previous two applications, a single prominent
feature (T297K) attains an MCC of 0.57; unlike the other problems, the next four features appear
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to be of about the same informative content (based on the order in which they are selected in
cross-validation folds), and MCC performance increases gradually as the features are added
(Figure 4.2). Interestingly, features previously reported as associated with HAD (see [51] for a
summary), are not added to the model until later: for example site 283 is the 8th ranked feature,
site 308 is the 38th, and site 304 is the 65th. Furthermore, the 90-feature IDEPI correctly classifies
all 10 individuals in the validation data set, whereas the original method correctly classified 8/10
cases.
4.4.5 Broadly neutralizing antibodies
Because IDEPI was designed for the specific problem of finding bNab epitopes and
predicting the resistance phenotype from sequence data, we compared its performance against
three recently published machine learning approaches to solving same problem.
1. Gnanakaran et al [41] proposed and tested an ensemble framework combining pattern
analysis and logistic regression to predict the neutralization phenotype and map the epitopes
of the b12 bNab[12], which targets the CD4 receptor binding site [69]. We used the
genotypic and associated phenotypic data from this study to train and test an IDEPI
classifier for the b12 bNab.
2. West et al [153] applied a direct optimization (implemented in the Antibody Database
program [ADP]) to predict the continuous IC50 value using sequence based features and
applied it to data from 25 antibodies. We compared the predictions derived by IDEPI
models for some of the same antibodies (chosen to represent one of the remaining three
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types of bNab classified by their targets [69]), using either publicly available neutralization
assay data, distributed with IDEPI, or the training data set from [17].
3. Chuang et al [17] developed an epitope feature selection which evaluates various measures
based on mutual information between sequence sites and IC50 values – an idea shared and
extended by the mRMR approach. We used the genotype and phenotype data for two of the
antibodies (8ANC131 and 8ANC195, the latter also studied by West et al) whose epitopes
were mapped and experimentally confirmed by Chuang et al.
2F5 bNab prediction 2F5 is the first characterized bNab which targets the linear Mem-
brane-Proximal External Region (MPER) region of HIV-1 viral envelope[90]. 2F5 provides a
natural baseline test case for IDEPI. On the one hand, any epitope prediction approach worth
its salt must perform well on this test case: the training dataset is one of the largest available,
the epitope is very well characterized [90], and the eptiope is short and linear (662-667 in the
HXB2 coordinates). On the other hand, 2F5 is an excellent example of a strong “clade effect”,
for example it neutralizes viruses of subtype B very well, but has essentially no potency against
subtype C viruses [44]. Thus, a machine learning approach could potentially learn a classification
model by simply finding genetic signatures that discriminate genetically divergent HIV-1 subtypes
and have little to do with antibody specificity; such behavior is clearly undesirable if one seeks
to find genetic determinants of resistance. On 2F5 data which we downloaded from the LANL
HIV CATNAP database (hiv.lanl.gov), IDEPI achieves the best MCC performance for all
bNab examined (0.81, Table 4.2) with a 3-feature model, demonstrating that it can learn “easy”
cases well. Not unexpectedly, the first feature selected by IDEPI is a K665K (Table 4.3), which
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is in the structurally characterized 2F5 epitope, and which alone yields the MCC of 0.73. The
second chosen feature (A667A) is also in the known epitope, but it improves cross-validation
MCC only to 0.75. West et al [153] identified the same two features in their model (as well as
three features outside the canonical epitope). The third feature in our model is not stable i.e. it is
not consistently chosen between CV replicates (e.g. T373T, K490E and E824G are chosen in
some of the replicates), and does not lie in the canonical epitope. The addition of a third feature
improves the sensitivity of the model (from 86.7% to 92.5%), while maintaining its specificity at
88.2%; further examination of the data indicates that the third is feature is necessary to correctly
classify the small proportion of sequences with resistant phenotypes which contain the sensitive
canonical epitope.
Because the current implementation IDEPI assumes that the contributions of individual
features to phenotype are independent and additive, it is possible that a feature in the model is not
directly involved with the phenotype but is only associated with other features that are. In this
context, the related features report may be useful: features that are strongly associated with those
already selected for the model by the mRMR algorithm are reported by IDEPI. More concretely,
if feature A is predictive of phenotype, feature B is only associated with phenotype due to shared
ancestry, and features A and B are themselevs strongly correlated, mRMR may choose feature B
as a part of the model and eliminate A from contention, but then IDEPI would report that A is
related to B. Hence, the correct interpretation of the genotypic features in the example would be
“either A or B are predictive of the phenotype”.
b12 bNab prediction Unlike the previous three applications, b12 epitope prediction
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results in both a simpler model (only 5 features) and a considerably lower performance (Table 4.2),
with an MCC of only 0.35. IDEPI achieves lower accuracy on the training data than the the
ensemble method developed by Gnanakaran et al [41] (note that the original reference does not
report a cross-validation value), but higher accuracy on validation data (Table 4.4), suggesting that
the ensemble model may have been over-fitting the training data. Only a single residue (D185D,
Table 4.3) is supported by the majority of cross-validation folds. Taken together, these results
suggest that the training data set is too small (or that the IDEPI feature set is suboptimal) to
reliably identify the complex structurally-defined epitope for b12. However, IDEPI outperforms
a previously published method on an independent validation dataset, and its 5-feature epitope
includes residue 424 which is a part of the CD4 binding site [53] targeted by the antibody.
Other broadly neutralizing antibodies
1. PG9 is a broadly neutralizing antibody targeting the V1/V2 loop in HIV-1 env [84], whose
canonical epitope is anchored by the PNGS at position 160, which is also the single most
important position in the 60-feature model fitted by IDEPI. A relatively low MCC of
0.42 is achieved, with the model showing fairly low sensitivity (0.49, Table 4.2). The 60
feature model has a remarkably high accuracy on the training data (0.96), but the small
number of resistant sequences in it makes it difficult to generalize the features past N160
(Figure 4.2). A direct comparison with West et al is difficult to formulate, because the
performance of ADP is measured by the proportion of IC50 variance explained by the
model, which cannot be measured for IDEPI. IDEPI finds the three features found by
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ADP, but ranks them differently (more in agreement with the structural studies): G732G
(resistant, ranked by ADP as having strong support, mean IDEPI feature rank 17.6/60),
PNGS (N160) (susceptible, supported by structure[84], ADP: intermediate support, IDEPI:
mean feature rank 7/60), and K171K (susceptible, supported by structure [84], ADP: strong
support, IDEPI: no 171 feature, but a number of features in neighboring positions 170,173
and 174). Further, IDEPI places another structurally confirmed residue in the inferred
epitope: V169E (resistant, mean rank 5/60), V169K (susceptible, mean rank 15/60)
2. PGT-121 is a broadly neutralizing antibody targeting glycans in the V3 loop [145]. IDEPI
infers a single feature model (Table 4.3), which associates the presence of a pair of PNGS (at
positions 301 and 332) as strongly predictive (MCC=0.58) of susceptibility. Interestingly,
while PNGS (N332) is the key part of the canonical PGT-121 epitope, PNGS (N301) –
previously thought relatively unimportant – appears to act together with N332 to effect
PGT-121 binding [60]. ADP predicts the importance of PNGS (N332), but also lists four
other sites whose role in antibody-virus interaction is unclear, and does not report N301 as
important.
3. 10E8 is a broadly neutralizing antibody that targets the MPER region [54] and shows
unusual potency versus the reference panel viruses. As a result, the training sample
(Table 4.2) includes only 4% of resistant sequences, and this makes meaningful learning
difficult, as evidenced by the low MCC of 0.23, and sensitivity of 0.30. There are no top
ranked features in the model (the ranking changes significantly between cross-validations,
Table 4.2), but one of the structurally defined epitope sites (T676T) is included among the
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top 5, whereas ADP finds no such sites and also performs poorly. The relevance of other
inferred model features associated with resistance, e.g. PNGS(T413+E824), K171E and
E153Q is questionable, and larger training datasets containing more resistant samples are
needed for computational prediction to improve.
4. 8ANC195 is a broadly neutralizing antibody whose epitope has not been structurally
confirmed [127], but it was used as a test case for computational epitope prediction and
experimental confirmation by two independent groups [153, 17]. IDEPI achieves a good
MCC of 0.67 on the training data from Chuang et al, and does so with only two features
in the epitope: two pairs of PNGS sites (Table 4.3). The top feature is that the absence
of either a PNGS anchored at site 234 or a PNGS anchored at site 276 confers resistance.
This single pair of PNGS subsumes three features (N234, N276, and T236) experimentally
validated by previous work. This example highlights that feature engineering (pairs of
PNGS) may provide a more compact description of neutralization features than either single
PNGS [153], or single residues [17] can. The second feature selected by IDEPI is another
pair of PNGS (N160 and N230), which is predicted to confer resistance, and does so at a
weak level [153].
5. 8ANC131 is a broadly neutralizing antibody whose epitope has been structurally mapped,
but not yet published [17], and the same authors performed computational prediction of
epitope sites and tested them experimentally. Unlike 8ANC195, where the epitope features
are clean and experimentally confirmed, computational predictions have not been found
nearly as useful, with the top sites conferring only marginal resistance [17]. IDEPI finds a
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diffuse signal for 15 features (Figure 4.2, Table 4.2), and an MCC of 0.19. There seems to
be little overlap between the features found in 3 or more cross-validation folds (susceptible:
K151G, V169R, resistant: N463K, D474N, PNGS(N339+Q442), PNGS(142a+N234)), and
those reported by [17] [top 10: 456,78,79,466,280,326,96,80,282,461] although many are
in the same region of the three-dimensional structure.
Computational Analysis for Real-Time Antibody Surveillance (CARTAS) Because IDEPI
is based on predictive modeling, we can use its prediction functionality to simulate the effective-
ness of characterized bNabs across the globe. To do so, all full-length gp160 sequences with
nation of origin annotations from Los Alamos National Laboratory’s (LANL) HIV-1 sequence
database were collected, and for each gp160 sequence, we predict its resistance/susceptibility
phenotype to each antibody for which we have training data. These predictions were combined
with Google’s Mapping API to produce an interactive map of the predicted efficacy of each
antibody or antibody combination for each nation represented in LANL’s database, which can be
found at http://monkeywrench.ucsd.edu/cartas. Maps corresponding to the global efficacy
of the b12 bNab and the PGT-family of bNabs can be found in Figure 4.3.
4.5 Availability and future directions
IDEPI and sklmrmr are installable via the PyPI Python package system through standard
tools (easy_install/pip), and their source code is available on GitHub (github.com/veg/
idepi and github.com/nlhepler/sklmrmr). A Virtual Machine for Oracle’s VirtualBox has
65
also been built to provide easy access to IDEPI for users unfamiliar with the intricacies of
Python package management, and is available from the main package distribution page (http:
//github.com/veg/idepi/).
IDEPI will likely be extended in the future to include a larger array of built-in feature ex-
traction mechanisms. For instance, because both amino-acid and nucleotide data can be useful for
phenotype prediction (the latter could be informative about important RNA secondary structures
in viruses, or transcription/translation efficiency), we will allow protein-coding sequences to be
tokenized into nucleotides and aminoacids jointly. In the future, we intend to release an update
that includes a feature extractor that maps sequence data to a provided structure to perform a
spatial neighborhood analysis, and an adaptive discretization algorithm for continuous features
(e.g. using Bayesian blocks [126]), required by mRMR. Downstream users that build novel
feature extractors are recommended to submit their creations to IDEPI, via GitHub’s pull request
mechanism, for inclusion in a future release. Additionally, in providing APIs compatible with
BioPython and scikit-learn, IDEPI will prove ever more useful as advances are made in those
fast-moving software packages. Finally, we encourage those who use IDEPI and learn models
using it to contribute these models by using the pull request mechanism available in GitHub.
Because the models do not include original sequence data, but only HMMER models needed to
make alignments, this mechanism also ensures privacy preservation of training data.
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4.7 Figures
Alignment
Feature extraction Cross-validation
Model learning
HMMER
SiteVectorizer
PairwiseSiteVectorizer
MotifVectorizer
PairwiseMotifVectorizer
mRMR SVM Model performancestatisticsLabeled sequences
Figure 4.1: IDEPI workflow. Abbreviations: MSA - multiple sequence analysis; mRMR -
minimum redundancy maximum relevance; SVM - support vector machine
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Figure 4.2: IDEPI performance, measured by MCC, as a function of the number of model
features. (A): on a representative of each of the four classification problems, (B): on predicting
resistance to a particular broadly neutralizing monoclonal antibody. Abbreviations: NVP -
Nevirapine; DRAM - drug resistance associated mutations; HAD - HIV associated dementia;
bNab - broadly neutralizing antibody. The optimal number of features is highlighted with a
filled circle for each line plot.
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non-B subtypes 
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Burton DR et al. Science 1994
Circle size denotes number of sequences sampledPGT-family
Walker LM et al. Nature 2011
Circle size denotes number of sequences sampled
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Figure 4.3: Examples maps predicting the effectiveness of th b12 and PGT-family of
antibodies. (b12, top) Since b12 was isolated from a subtype B individual, it is not effective in
countries where non-B subtypes predominate. (PGT-family, bottom) PGT nAbs were isolated
from 4 individuals infected with different subtypes and targeting different epitopes in gp160,
suggesting broad coverage. In both figures the size of the circle denotes the number of
sequences contributing in the predicted efficacy.
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Chapter 5
Conclusions and Outlook
5.1 Ultra-deep sequencing analysis
The UDS pipeline, in particular the codon-aware alignment algorithm and error correction
techniques, have been used in several studies: the identification of co- and super-infection [95],
the characterization of immune response to superinfection [144, 15], characterizing the global
transmission network of HIV-1 [151], and inference of the SD PIC transmission network using
NGS data (Chapter 3). In particular, evolutionary models of sequence similarity (e.g. TN93,
HKY85), better capture important variation than naïve p-distance, and permit more accurate
recovery of potential transmission events. Alignment algorithms that are robust to sequencing
error and preserve codon information facilitate the application of these models.
While the Roche 454 platform is being phased out, and the now-predominant Illumina
technology is less prone to in-del errors, the so-called 3rd-generation Pacific Biosciences (PacBio)
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sequencing technology suffers from an error model similar to that of the 454 platform. In
particular, the hompolymer length miscall problem arises in many instruments due to the robust
information provided by a change of base (e.g. a change of color), against the limited information
communicated between two or more identical bases (e.g. a change of amplitude, or the distinction
of separate “pulses”). The techniques we developed for analyzing 454 data have been successfully
applied to PacBio data, reconstructing a phylogeny of intrapatient evolution from UDS env data
collected at 3 time points (Figure 2.3).
The UDS pipeline, which bundles best practices with an easy-to-use interface, empowers
virologists to use NGS technologies and UDS approaches to viral characterization. It is applicable
beyond HIV-1, to the analysis of data from any organism where the resolution provided by UDS
data would be useful (e.g. hepatitis C). As sequencing technologies change and evolve, so must
the methods employed by the pipeline. For example, one could add branch and merge moves to
the codon-aware alignment algorithm to directly address homopolymer in-del errors in PacBio
data. The sequencing error estimator and variant caller can incorporate ideas from competing
methods to gain additional power, for example the covariant information leveraged by V-Phaser
[82] or the point-spread function estimation leveraged by LoFreqNQ [155]. Depending on the
application, properly using sequence data with a high error rate such as PacBio may necessitate
accounting for reference bias during alignment [14], which can be addressed with partial-order
alignment techniques [73].
New analyses can be added to the pipeline, such as haplotype analysis, once reliable
methods are invented that either incorporate, or can be modified to incorporate, a codon-aware
77
philosophy. Current haplotype inference techniques are limited in their performance [128], and do
not incorporate codon-awareness limiting their use in preparing data for downstream evolutionary
analysis.
Incorporating best practices into a single, easy-to-use pipeline facilitates the use of NGS
data by virologists, empowering them to focus on elucidating the dynamics of their virus rather
than developing infrastructure and methods for analyzing NGS data, whose size and complexity
pose difficult challenges.
5.2 NGS network inference and dual infection
The inference of transmission networks is one of the most immediately useful applications
of sequencing to the study of epidemiology, in particular for venereal diseases: patients are
less than reliable about reporting their sexual behavior and history. While bulk sequencing
of viral RNA from plasma is currently standard for HIV-1 sequencing, it is of limited utility
in characterizing intra-patient diversity, identifying minor variants for the purposes of drug-
resistance associated mutation testing, and may potentially become more costly than NGS as the
latter continues to drive down the costs of sequencing. The NGS network analysis in Chapter
3 demonstrates the value and utility of employing NGS technologies and UDS methodologies
to transmission network inference: the result was more complete and phenomologically useful
(e.g. dual infection) than the result derived from bulk sequences alone. As NGS sequencing
data becomes more prevalent, the technique demonstrated in Chapter 3 (or similar techniques)
will be used for inferring molecular transmission networks, increasing the resolution of onward
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transmission events (e.g. of minor subpopulations), and permitting broader investigation into the
role of dual infection in viral epidemiology, which is already a nascent and rapidly expanding
niche of HIV-1 research.
5.3 IDEPI and epitope prediction
My work on IDEPI highlights an interesting development in bioinformatics research:
the development of specialized models when use of standard techniques perform similarly or
superiorly. In particular, tools such as IDEPI can be ignorant of the specifics of the problem
domain yet still provide biologically useful results, results which suggest paths forward for
greater understanding–this was in fact the raison d’être of IDEPI, to, in complete ignorance of
epitope mechanics, predict the most favorable sites to interrogate for antibody binding with costly
biochemical validation. As the state-of-the-art in feature selection and classifiction advances,
with minimal modification so will IDEPI, letting users focus on their problem domain rather
than plumbing. And the use of predictive modeling provides immediate utility in the form of a
predictor whose performance is already well-characterized via cross-validation.
The future of epitope prediction lies in adopting a generalized machine learning (ML)
approach–specialized models lack the flexibility necessary to perform well on the variety of
epitopes currently discovered. The combination of multiple feature generation techniques with
state-of-the-art ML algorithms have promise to provide a robust path forward for high-throughput
characterization of antibody epitopes–necessary as we try to develop a more targeted approach
to vaccine design that, at present, appears necessary to effectively halt the spread of the HIV-1
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epidemic.
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Appendix A
The central role of HIV-1 dual infection in
molecular transmission networks revealed
by next generation sequencing
A.1 Supplementary information
A.1.1 Brief cohort description
HIV-1 screening was offered to adults and adolescents between 1996 and 2013 at multiple
HIV-1 testing and counseling sites in San Diego, California [88]. All HIV-positive individuals
were offered study participation with confidential partner services. All persons identified with
recent infection who were antiretroviral treatment (ART)-naïve formed the San Diego Primary
Infection Cohort (SD PIC). HIV-1 screening was also provided to recent sexual and social
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network contacts of newly infected participants. The UCSD Human Research Protections
Program approved the study protocol, consent and procedures for consent. All study participants
provided voluntary, written informed consent before any study procedures were undertaken. An
estimated date of infection (EDI) was computed for all recently infected participants, using a
previously described algorithm [71] (Supplemental Table S1) Although ART was not provided,
treatment was generally encouraged. The demographics of the HIV-1 epidemic in San Diego
mirror those of the U.S. epidemic as a whole, since self-identified MSM represent the majority of
prevalent (66%) and incident (53%) HIV-1 infections in the U.S. The preponderance of the MSM
population (91% of SD PIC and 77% of infections county-wide), and the strong representation of
communities of color (Hispanics represent 21% of SD PIC and 24% of infections county-wide) in
the HIV-infected San Diego community, demonstrates that SD PIC recruits from representative
at-risk populations in San Diego [131].
A.1.2 Sequencing procedures and QC
Three coding regions–gag p24 (HXB2 coordinates 1366–1619), pol reverse transcriptase
(RT, HXB2 coordinates 2708–3242), and env C2-V3 (HXB2 coordinates 6928–7344)–were
amplified by polymerase chain reaction (PCR) with region-specific primers, and rubber gaskets
were used to physically separate 16 concurrently sequenced samples on a single 454 GS FLX
titanium picoliter plate (454 Life Sciences/Roche, Branford, CT) [38, 94, 95, 143].To avoid cross-
contamination, extraction procedures, PCR and NGS library preparation of samples from the
same cohort participants were performed on different days and in different sequencing runs. The
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methodology for NGS analysis has been described in detail elsewhere [95]. Briefly, high-quality
reads were retained and aligned to HXB2 library reference genes for the 3 coding regions using an
iterative codon-based alignment procedure, and the maximum divergence (MDI) was calculated
for each coding region as the maximum likelihood divergence using the HKY85 substitution
model in sliding windows of 150 nucleotides (50-nucleotide shifts, minimum site coverage 500
reads).
A.1.3 Procedure for detecting dual infection using NGS
Putative DI was suggested when the maximum nucleotide divergence (MDI) of a sample
(estimated using the phylogenetic procedure described previously [94]) was >5% in env and
>2.5% in gag and pol. If the MDI exceeded these thresholds in at least one coding region,
additional phylogenetic analyses (neighbor-joining and maximum likelihood tree reconstruction
and bootstrapping) were performed and highlighter plots were created using 500 randomly
selected reads, and if 2 phylogenetic clusters were separated by a branch with a bootstrap value
>90%, the sample was preliminarily classified as DI. Representative haplotypes were then input
into BLAST against a database of locally generated reads to assess for contamination, and
if none was found, a different plasma aliquot from the same time point (or within-3-months)
underwent repeat RNA extraction, cDNA generation, and NGS to confirm DI. If DI was not
observed in the repeat sample, the participant was classified as monoinfected. Longitudinal viral
sequences for each coding region from a participant were also assembled into a single phylogeny
to further assess for evidence of DI that could be missed by focusing solely on intrasample genetic
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relatedness (i.e, superinfection with viral replacement). Coinfection was defined as DI at baseline,
and superinfection was defined as monoinfection at baseline and DI at a later time point. The
algorithm for the selection of time points for sampling was described elsewhere [95].
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A.1.4 Tables
Table A.1: Inferred disease stage (see [71] for definitions) for the 348 individuals in the
connected components of the transmission network (A – acute, E – early)
EDI Stage Connect in network Total
Count (proportion) Count (proportion)
A-1 50 (14.4%) 105 (16.2%)
A-2 7 (2.0%) 12 (1.9%)
A-3 10 (2.9%) 21 (3.2%)
E-1 162 (46.6%) 280 (43.2%)
E-2 23 (6.6%) 36 (5.6%)
Chonic 96 (27.6%) 194 (29.9%)
Total 348 (100%) 648 (100%)
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Table A.2: NGS library information for each of the sequenced participants. For individuals
with an available estimated date of infection (EDI), sample dates are listed relative to the EDI;
for others (chronically infected), the dates are listed as month/year. For each patient, the dual
infection status is indicated: SI – superinfection, CI – coinfection. A successful replicate was
defined as having median sequenced region coverage of 500 or greater. There are five dually
infected individuals marked with (*): the DI status of these individuals was originally
determined using single genome sequencing and confirmed using NGS of a single time-point
[94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
(CI) 050100478 Jul-97 2 (1211.25) 3 (3752) 2 (2687.0)
(CI) 050101225 11 wks post EDI 3 (1053.0) 4 (8132.5) 4 (1127.5)
(CI) 050104211 65 wks post EDI 2 (1195.5) 0 0
(CI) 050105334* 12 wks post EDI 1 (896.0) 1 (13540) 1 (9418)
(CI) 050107185* 74 wks post EDI 1 (1782.5) 1 (8621) 1 (44905)
(CI) 050108085 24 wks post EDI 9 (3239.5) 7 (4009) 9 (7435)
(CI) 050109925 10 wks post EDI 2 (1270.0) 2 (2870.5) 2 (2366.0)
12 wks post EDI 1 (2530.0) 1 (13710) 1 (2941)
(SI) 050100552 50 wks post EDI 1 (6657.0) 1 (35111) 1 (19853)
306 wks post EDI 2 (4662.5) 2 (7236.5) 2 (797.5)
(SI) 050101277 10 wks post EDI 1 (3845.5) 1 (3687) 1 (4188)
11 wks post EDI 3 (4821.5) 3 (9547) 1 (7750)
31 wks post EDI 1 (8419.5) 1 (19745) 1 (20296)
44 wks post EDI 0 1 (2860) 0
52 wks post EDI 0 0 0
61 wks post EDI 0 0 1 (689)
89 wks post EDI 1 (5464.0) 1 (10656) 1 (14222)
123 wks post EDI 1 (2109.5) 1 (4543) 1 (648)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
127 wks post EDI 1 (7208.5) 1 (4155) 1 (2045)
136 wks post EDI 1 (3616.0) 1 (13820) 1 (8746)
(SI) 050102584* 22 wks post EDI 3 (4328.5) 2 (6022.5) 3 (9359)
(SI) 050102826 30 wks post EDI 1 (6008.5) 0 1 (3615)
34 wks post EDI 1 (9031.0) 1 (12675) 1 (4913)
61 wks post EDI 0 1 (1795) 0
(SI) 050104359 24 wks post EDI 1 (7035.0) 1 (15298) 1 (4019)
37 wks post EDI 1 (1798.5) 1 (12819) 1 (3669)
40 wks post EDI 1 (9983.0) 1 (4099) 1 (1087)
54 wks post EDI 7 (3507.0) 5 (13713) 5 (4472)
(SI) 050106508 10 wks post EDI 4 (1430.5) 4 (11697.0) 4 (1448.0)
130 wks post EDI 2 (3291.75) 2 (6426.5) 2 (5965.0)
142 wks post EDI 2 (2776.0) 2 (5461.0) 2 (5572.5)
(SI) 050106846* 150 wks post EDI 1 (675.0) 1 (4330) 1 (3321)
(SI) 050108007 24 wks post EDI 2 (1205.0) 2 (2999.5) 2 (1279.5)
49 wks post EDI 1 (8679.0) 1 (12674) 1 (6642)
55 wks post EDI 1 (1261.0) 1 (5453) 1 (990)
69 wks post EDI 1 (4853.0) 1 (6520) 1 (1789)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
77 wks post EDI 1 (7933.5) 1 (10552) 1 (3099)
86 wks post EDI 1 (10520.5) 1 (12245) 1 (4617)
96 wks post EDI 1 (16375.5) 1 (28696) 1 (18447)
107 wks post EDI 1 (7872.5) 1 (8101) 1 (4461)
116 wks post EDI 2 (7132.5) 2 (6637.5) 2 (2031.0)
(SI) 050108443* 10 wks post EDI 1 (2311.5) 1 (14305) 1 (7559)
(SI) 050110285 10 wks post EDI 2 (996.5) 2 (3309.0) 2 (2184.0)
21 wks post EDI 2 (21367.75) 2 (6915.0) 2 (45844.0)
50100011 3 wks post EDI 1 (2246.5) 1 (3278) 1 (3943)
8 wks post EDI 0 2 (10521.5) 2 (2789.5)
286 wks post EDI 4 (2615.75) 4 (4425.5) 4 (3784.5)
50100048 3 wks post EDI 1 (16545.5) 1 (10626) 0
50100307 Mar-97 2 (5557.75) 2 (1224.5) 2 (885.0)
Dec-03 1 (1749.5) 1 (716) 2 (4290.0)
Dec-03 1 (2063.5) 1 (10576) 0
50100402 Jun-97 0 0 0
50100444 3 wks post EDI 1 (1985.5) 1 (8741) 1 (4381)
11 wks post EDI 0 2 (12819.0) 1 (972)
88
Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50100595 269 wks post EDI 1 (3106.0) 1 (17652) 1 (12181)
50100753 54 wks post EDI 1 (1099.0) 1 (2343) 1 (9998)
50100839 67 wks post EDI 1 (742.5) 1 (11518) 1 (10148)
50100991 20 wks post EDI 1 (6952.5) 1 (7373) 1 (3171)
129 wks post EDI 1 (1078.5) 1 (6473) 1 (2229)
284 wks post EDI 3 (2346.5) 3 (6431) 5 (9464)
50101087 Apr-99 4 (852.0) 1 (24899) 5 (2084)
50101117 May-99 1 (705.0) 1 (1373) 0
50101128 120 wks post EDI 4 (1198.75) 0 3 (595)
50101134 52 wks post EDI 1 (1525.5) 1 (12518) 1 (7145)
50101142 321 wks post EDI 1 (560.0) 1 (1020) 1 (3101)
50101351 Apr-00 2 (2412.5) 2 (2970.5) 2 (954.0)
50101433 13 wks post EDI 2 (5299.75) 2 (9593.5) 2 (3067.0)
24 wks post EDI 2 (2800.5) 2 (8681.5) 2 (1086.0)
32 wks post EDI 2 (2768.0) 2 (5027.0) 0
50101510 254 wks post EDI 1 (712.5) 0 2 (2134.0)
50101679 41 wks post EDI 1 (2607.5) 1 (13440) 1 (4344)
50101692 Jun-01 0 1 (1293) 1 (4750)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50101808 25 wks post EDI 2 (4074.25) 2 (7505.0) 2 (7282.5)
192 wks post EDI 1 (2140.5) 1 (13422) 1 (4287)
50101814 Dec-03 1 (2957.5) 1 (13572) 1 (7879)
50101820 Feb-01 0 2 (3834.0) 2 (707.0)
50101837 29 wks post EDI 2 (2131.5) 2 (5736.0) 2 (1647.5)
50101967 10 wks post EDI 4 (4408.5) 4 (9635.0) 4 (4306.5)
15 wks post EDI 1 (1231.0) 1 (9358) 1 (10456)
50102019 10 wks post EDI 1 (6942.0) 1 (10313) 1 (3550)
15 wks post EDI 1 (8666.5) 1 (7026) 1 (3121)
40 wks post EDI 1 (16672.5) 1 (24960) 1 (5650)
121 wks post EDI 3 (4277.0) 3 (5538) 3 (4505)
50102040 19 wks post EDI 1 (5346.5) 1 (8587) 1 (5797)
33 wks post EDI 1 (9716.0) 1 (14633) 1 (4336)
46 wks post EDI 1 (11300.0) 1 (13248) 1 (2783)
50102066 Nov-00 2 (1256.0) 2 (13858.5) 2 (4616.0)
50102135 6 wks post EDI 1 (3164.0) 1 (8916) 1 (8264)
50102148 10 wks post EDI 1 (8521.5) 1 (15842) 1 (6314)
25 wks post EDI 1 (1679.0) 1 (11648) 1 (4812)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
30 wks post EDI 1 (8585.0) 1 (7446) 1 (1186)
50102163 61 wks post EDI 1 (4009.0) 1 (1456) 1 (3387)
50102197 11 wks post EDI 2 (7788.25) 2 (8625.0) 2 (1915.0)
19 wks post EDI 1 (7070.0) 0 2 (3110.0)
53 wks post EDI 2 (2876.5) 2 (8826.0) 2 (4229.5)
84 wks post EDI 1 (1522.0) 1 (14603) 1 (4124)
50102213 10 wks post EDI 3 (3010.0) 2 (2872.0) 4 (1882.0)
50102246 10 wks post EDI 4 (1338.5) 3 (1402) 4 (5410.5)
50102260 Mar-01 2 (2619.0) 2 (6017.0) 0
Jun-01 1 (5193.0) 1 (19359) 0
Mar-02 2 (1237.5) 2 (7620.0) 2 (4341.5)
Sep-02 2 (3035.0) 2 (5842.5) 2 (3387.5)
50102318 19 wks post EDI 1 (1561.5) 1 (7301) 1 (2090)
50102333 71 wks post EDI 3 (2268.0) 3 (1282) 3 (4265)
50102341 10 wks post EDI 1 (4362.5) 1 (9632) 1 (4750)
68 wks post EDI 4 (3540.25) 4 (8414.0) 5 (8354)
50102357 3 wks post EDI 2 (3203.75) 2 (16912.5) 2 (7998.0)
50102527 59 wks post EDI 1 (937.5) 0 1 (3035)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50102859 78 wks post EDI 0 1 (1154) 1 (1154)
50102953 11 wks post EDI 2 (1628.5) 1 (8171) 1 (5887)
50104001 10 wks post EDI 1 (869.0) 0 1 (1891)
50104027 10 wks post EDI 1 (5318.0) 0 1 (901)
47 wks post EDI 1 (12699.5) 1 (5308) 1 (642)
50104055 19 wks post EDI 1 (6431.0) 1 (15733) 1 (10300)
50104114 77 wks post EDI 1 (2242.5) 1 (11290) 1 (4364)
50104120 11 wks post EDI 2 (8738.5) 2 (6656.5) 2 (919.5)
27 wks post EDI 0 1 (33163) 1 (4981)
50104137 31 wks post EDI 1 (4176.0) 1 (14370) 1 (7552)
50104206 10 wks post EDI 3 (1648.0) 6 (4450.5) 8 (1413.0)
50104250 Feb-02 1 (3054.0) 1 (11165) 1 (8654)
Oct-02 4 (3132.75) 4 (5890.5) 4 (3399.0)
Sep-03 4 (2370.0) 4 (3788.0) 4 (807.5)
50104263 29 wks post EDI 1 (3808.0) 2 (8654.0) 1 (3281)
50104407 53 wks post EDI 0 0 1 (6843)
104 wks post EDI 1 (5510.0) 1 (15377) 1 (4233)
50104498 8 wks post EDI 2 (7686.25) 2 (10707.0) 2 (5152.0)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
278 wks post EDI 0 1 (2083) 1 (2656)
50104533 11 wks post EDI 2 (2284.5) 2 (5709.0) 2 (3420.5)
25 wks post EDI 1 (5407.5) 1 (17641) 1 (9030)
48 wks post EDI 1 (2196.5) 1 (7939) 1 (5711)
56 wks post EDI 0 1 (775) 1 (2256)
50104652 May-02 1 (7198.0) 1 (6757) 1 (12224)
50104834 19 wks post EDI 1 (3207.0) 1 (9015) 1 (9545)
50104869 Jul-02 1 (2875.0) 1 (13480) 1 (1941)
50105033 2 wks post EDI 4 (2492.5) 4 (3551.5) 3 (865)
22 wks post EDI 1 (1295.0) 1 (4980) 1 (3864)
50105076 10 wks post EDI 1 (12858.0) 1 (3549) 1 (1117)
73 wks post EDI 6 (4244.75) 6 (8510.5) 6 (3439.0)
216 wks post EDI 1 (3018.0) 1 (6086) 1 (5655)
50105123 10 wks post EDI 1 (7652.5) 1 (10559) 1 (5185)
151 wks post EDI 1 (6458.5) 1 (8089) 1 (1397)
183 wks post EDI 1 (3128.0) 2 (1223.0) 2 (1561.0)
50105164 10 wks post EDI 1 (12138.0) 1 (11557) 1 (4916)
82 wks post EDI 1 (6749.0) 1 (17389) 1 (4921)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50105196 35 wks post EDI 0 1 (3393) 1 (1353)
50105237 24 wks post EDI 1 (2613.0) 1 (9487) 1 (6098)
25 wks post EDI 1 (3620.0) 1 (11571) 1 (3895)
173 wks post EDI 1 (6811.5) 1 (21293) 1 (5675)
233 wks post EDI 3 (2309.0) 2 (5493.5) 3 (1622)
50105245 10 wks post EDI 1 (8813.0) 1 (23239) 1 (4432)
14 wks post EDI 1 (2522.5) 1 (8256) 1 (6779)
50105272 12 wks post EDI 1 (5387.0) 1 (13980) 1 (2682)
180 wks post EDI 7 (1607.0) 2 (13031.0) 2 (5871.0)
50105317 16 wks post EDI 1 (11782.5) 1 (6942) 0
104 wks post EDI 3 (7115.5) 3 (15382) 3 (1353)
50105328 7 wks post EDI 1 (6492.0) 1 (12130) 1 (6422)
23 wks post EDI 1 (7386.0) 1 (15837) 1 (4996)
30 wks post EDI 1 (5498.0) 1 (6258) 1 (1640)
34 wks post EDI 4 (4518.0) 4 (11890.0) 5 (3231)
50105471 15 wks post EDI 1 (2630.0) 1 (14490) 1 (5403)
45 wks post EDI 1 (16538.0) 1 (6024) 1 (2897)
50105578 10 wks post EDI 1 (5550.0) 1 (2143) 1 (3435)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50105580 12 wks post EDI 1 (6744.5) 1 (9972) 1 (5129)
14 wks post EDI 1 (12710.0) 1 (13718) 1 (4519)
20 wks post EDI 1 (9534.0) 1 (11460) 1 (6430)
50105593 2 wks post EDI 1 (7129.5) 1 (10425) 1 (3684)
6 wks post EDI 1 (9350.0) 1 (10465) 1 (3909)
109 wks post EDI 1 (1356.0) 1 (7185) 1 (2479)
169 wks post EDI 1 (3452.5) 1 (6653) 1 (6569)
217 wks post EDI 1 (10391.0) 1 (17144) 1 (4390)
50105648 Feb-03 1 (9491.0) 1 (13123) 1 (4766)
50105663 10 wks post EDI 1 (6858.0) 1 (6908) 1 (2953)
125 wks post EDI 4 (1502.5) 4 (2261.0) 7 (753)
50105755 150 wks post EDI 2 (5618.75) 2 (4694.0) 2 (4852.5)
50105819 24 wks post EDI 4 (3400.75) 4 (8181.0) 4 (5264.0)
25 wks post EDI 1 (4697.0) 1 (9214) 1 (2917)
41 wks post EDI 1 (1795.0) 1 (9398) 1 (4861)
50105825 11 wks post EDI 1 (5868.0) 1 (12558) 1 (7855)
50105866 166 wks post EDI 1 (3388.0) 1 (10237) 1 (8555)
50106070 Apr-03 2 (5972.0) 2 (7993.0) 2 (2810.5)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50106259 124 wks post EDI 0 0 0
50106293 12 wks post EDI 1 (7588.0) 1 (19938) 1 (4062)
66 wks post EDI 1 (1212.0) 1 (10857) 1 (1631)
82 wks post EDI 1 (1686.5) 1 (11983) 1 (2306)
257 wks post EDI 2 (12992.0) 0 1 (2833)
50106311 157 wks post EDI 0 0 0
50106335 21 wks post EDI 5 (3567.5) 8 (6257.0) 7 (3795)
26 wks post EDI 1 (6697.5) 1 (5039) 1 (2838)
38 wks post EDI 1 (3223.0) 1 (9130) 1 (7947)
50106754 27 wks post EDI 1 (3294.5) 3 (5530) 2 (5422.0)
50106824 87 wks post EDI 1 (1596.5) 1 (8283) 1 (6350)
50106916 151 wks post EDI 1 (2601.0) 1 (14063) 1 (6666)
50106927 18 wks post EDI 1 (1605.5) 1 (17056) 1 (6072)
162 wks post EDI 2 (3314.0) 2 (9983.5) 2 (6545.5)
258 wks post EDI 1 (6259.0) 1 (6373) 1 (1097)
50106930 Oct-03 1 (6912.0) 1 (10125) 1 (3834)
50107026 10 wks post EDI 2 (3710.75) 2 (22804.0) 2 (7804.0)
16 wks post EDI 1 (5838.0) 1 (13910) 1 (5224)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
107 wks post EDI 1 (3479.5) 1 (12102) 1 (3528)
180 wks post EDI 2 (4825.0) 2 (9478.0) 2 (5738.5)
50107110 Nov-03 1 (5277.0) 1 (6074) 1 (3760)
50107136 142 wks post EDI 1 (3039.5) 0 1 (3503)
50107173 99 wks post EDI 1 (1638.0) 1 (4501) 1 (3625)
50107198 Nov-03 1 (7088.5) 1 (15099) 1 (4989)
50107212 3 wks post EDI 1 (7318.0) 1 (7481) 1 (2556)
50107239 10 wks post EDI 1 (5213.0) 2 (4024.5) 3 (1534)
35 wks post EDI 1 (2086.0) 1 (12121) 1 (2127)
81 wks post EDI 1 (1068.0) 1 (12679) 1 (3959)
50107288 1 wks post EDI 1 (5094.5) 1 (8076) 1 (3159)
5 wks post EDI 4 (1981.0) 5 (3264) 3 (1820)
50107296 29 wks post EDI 1 (5663.0) 1 (20900) 1 (6656)
122 wks post EDI 1 (8819.0) 1 (14835) 1 (4649)
135 wks post EDI 4 (7313.25) 4 (6374.0) 4 (2503.5)
156 wks post EDI 3 (3951.0) 3 (9991) 1 (4208)
50107332 4 wks post EDI 1 (6825.5) 1 (14597) 1 (5939)
4 wks post EDI 1 (8358.5) 1 (14482) 1 (7734)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
28 wks post EDI 3 (812.0) 3 (3865) 1 (2330)
110 wks post EDI 2 (6688.75) 2 (17154.5) 2 (4489.5)
122 wks post EDI 3 (3282.0) 4 (9646.0) 2 (7001.0)
140 wks post EDI 1 (3845.0) 1 (7830) 1 (2570)
50107394 142 wks post EDI 1 (1802.0) 1 (14513) 1 (8067)
50107422 93 wks post EDI 1 (1007.5) 1 (13937) 1 (3199)
50107448 Dec-03 2 (4344.0) 2 (9118.0) 2 (3015.0)
Jan-04 1 (16284.0) 1 (16594) 1 (3282)
50107517 Jan-04 1 (5536.0) 1 (7463) 1 (8561)
Feb-04 1 (10494.5) 1 (14867) 1 (5313)
50107556 17 wks post EDI 1 (8385.5) 1 (10113) 1 (3317)
57 wks post EDI 1 (990.0) 1 (3607) 0
50107569 19 wks post EDI 2 (501.5) 2 (14785.0) 2 (3193.0)
20 wks post EDI 1 (7885.5) 1 (4294) 1 (1955)
38 wks post EDI 1 (2386.0) 1 (10023) 1 (3743)
50107591 24 wks post EDI 3 (5670.5) 3 (7178) 3 (4203)
31 wks post EDI 1 (8559.5) 1 (11610) 1 (2545)
40 wks post EDI 1 (10140.0) 1 (11186) 1 (1903)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
67 wks post EDI 1 (673.0) 1 (9795) 1 (5881)
50107608 Feb-04 1 (9169.5) 1 (13712) 1 (6919)
Feb-04 1 (978.0) 1 (3588) 0
50107661 19 wks post EDI 2 (4088.25) 2 (8774.5) 2 (3308.0)
20 wks post EDI 2 (3420.5) 2 (20081.5) 2 (7024.0)
21 wks post EDI 1 (5375.5) 1 (21498) 1 (4254)
33 wks post EDI 1 (875.0) 1 (5695) 1 (2220)
50107790 10 wks post EDI 2 (2744.0) 2 (4038.5) 2 (5374.0)
53 wks post EDI 0 0 2 (11480.5)
112 wks post EDI 1 (3004.5) 1 (12410) 1 (9544)
50107801 19 wks post EDI 4 (2417.25) 3 (4621) 4 (3105.5)
20 wks post EDI 1 (2454.0) 1 (11761) 1 (3348)
30 wks post EDI 1 (1213.0) 1 (2921) 1 (9612)
50107827 10 wks post EDI 4 (6194.5) 4 (9481.0) 4 (5785.5)
10 wks post EDI 1 (1844.0) 1 (9810) 1 (2325)
23 wks post EDI 0 1 (4996) 1 (4655)
50107952 26 wks post EDI 1 (8493.5) 1 (5530) 1 (6443)
72 wks post EDI 2 (6522.0) 3 (5666) 2 (1916.0)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
175 wks post EDI 2 (5926.0) 2 (9730.0) 2 (6854.5)
220 wks post EDI 1 (4226.0) 1 (7508) 1 (1301)
50107971 10 wks post EDI 2 (2670.5) 2 (3426.5) 2 (4225.5)
11 wks post EDI 1 (537.0) 1 (12725) 1 (6208)
18 wks post EDI 1 (3901.5) 1 (13644) 1 (3181)
50107987 1 wks post EDI 3 (8358.5) 3 (6666) 3 (4991)
50108010 24 wks post EDI 1 (6806.0) 1 (9435) 1 (1779)
34 wks post EDI 1 (3445.5) 1 (8350) 1 (1625)
122 wks post EDI 3 (5627.0) 3 (9267) 3 (1418)
50108062 9 wks post EDI 1 (9321.0) 1 (12549) 1 (8356)
63 wks post EDI 5 (5326.0) 5 (3650) 5 (1927)
136 wks post EDI 2 (4146.0) 2 (5676.0) 2 (2936.0)
50108098 May-04 1 (12145.0) 1 (10035) 1 (7598)
50108102 27 wks post EDI 1 (15500.0) 1 (14183) 1 (4951)
180 wks post EDI 4 (2582.0) 4 (7624.5) 5 (5421)
50108193 10 wks post EDI 1 (9649.0) 1 (8100) 1 (5805)
27 wks post EDI 1 (6888.5) 1 (5367) 1 (1564)
79 wks post EDI 1 (2480.5) 1 (5625) 1 (2759)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
117 wks post EDI 8 (3395.5) 6 (12207.0) 8 (6421.5)
50108256 13 wks post EDI 4 (2864.75) 4 (9202.5) 4 (3571.0)
46 wks post EDI 1 (1965.0) 1 (11186) 1 (7009)
66 wks post EDI 0 0 2 (7247.0)
50108283 19 wks post EDI 1 (1500.0) 1 (6515) 1 (5131)
25 wks post EDI 4 (2763.5) 4 (9057.0) 4 (8606.0)
54 wks post EDI 4 (2831.5) 4 (5125.0) 4 (1559.0)
76 wks post EDI 1 (10499.5) 1 (21021) 1 (3553)
50108291 1 wks post EDI 1 (6078.0) 1 (12155) 1 (5132)
2 wks post EDI 1 (6291.0) 1 (12984) 1 (5832)
4 wks post EDI 1 (1638.0) 1 (5005) 1 (984)
57 wks post EDI 1 (6303.5) 1 (9700) 1 (5032)
83 wks post EDI 1 (6131.5) 1 (9970) 1 (1536)
107 wks post EDI 2 (5210.5) 2 (8861.0) 2 (4405.5)
125 wks post EDI 1 (12145.0) 1 (10689) 1 (3447)
50108353 55 wks post EDI 1 (620.0) 1 (16899) 1 (7029)
50108401 13 wks post EDI 1 (5448.0) 1 (9576) 1 (3801)
30 wks post EDI 1 (2212.5) 1 (11314) 1 (2382)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
33 wks post EDI 1 (1054.0) 1 (18392) 1 (1953)
77 wks post EDI 2 (3744.25) 4 (5688.5) 3 (1297)
50108625 Sep-04 3 (2338.5) 2 (3242.0) 3 (590)
50108752 10 wks post EDI 3 (4802.0) 3 (15492) 3 (3121)
11 wks post EDI 1 (4135.0) 1 (16069) 1 (4317)
81 wks post EDI 3 (7166.5) 3 (1372) 3 (2153)
50108933 May-08 0 0 0
50109667 1 wks post EDI 1 (4480.0) 1 (15967) 1 (5102)
50109680 19 wks post EDI 2 (7107.0) 2 (9791.0) 2 (6372.0)
50110028 1 wks post EDI 1 (5057.0) 1 (4213) 1 (9772)
50110187 26 wks post EDI 1 (12399.0) 1 (17288) 1 (8689)
38 wks post EDI 1 (22090.0) 1 (27530) 1 (15532)
66 wks post EDI 1 (13844.0) 1 (22406) 1 (5626)
50110195 Nov-05 1 (8041.0) 1 (6336) 1 (13342)
Dec-05 1 (8423.5) 1 (7696) 1 (6679)
50110210 19 wks post EDI 0 1 (8015) 1 (4388)
21 wks post EDI 1 (2808.0) 1 (5021) 1 (966)
35 wks post EDI 1 (12810.5) 1 (8299) 1 (1812)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
50110221 10 wks post EDI 1 (4581.0) 1 (10938) 1 (2719)
17 wks post EDI 1 (4855.0) 1 (15355) 1 (2511)
25 wks post EDI 1 (8928.0) 1 (15094) 1 (4086)
45 wks post EDI 1 (10907.0) 1 (16214) 1 (5875)
50110236 12 wks post EDI 2 (3128.75) 2 (4695.5) 2 (1294.0)
18 wks post EDI 0 2 (7572.0) 2 (1080.0)
62 wks post EDI 2 (4307.5) 2 (7883.0) 0
50110254 Dec-05 1 (10874.5) 1 (11187) 1 (2625)
50111189 10 wks post EDI 1 (6047.0) 1 (15183) 1 (3546)
17 wks post EDI 1 (14038.5) 1 (10379) 1 (1847)
50111412 1 wks post EDI 1 (7521.0) 1 (8663) 1 (4334)
50111447 10 wks post EDI 2 (7393.75) 2 (7243.0) 2 (5469.0)
50112024 11 wks post EDI 1 (5943.0) 1 (11340) 1 (5013)
50112071 Sep-08 2 (7040.5) 2 (6015.0) 2 (9014.0)
50112351 1 wks post EDI 1 (8637.5) 1 (6668) 1 (3273)
5 wks post EDI 1 (11039.0) 1 (6779) 1 (5093)
21 wks post EDI 1 (12403.0) 1 (8910) 1 (5752)
50112429 Feb-09 2 (4521.5) 2 (4289.0) 2 (4226.0)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
Feb-09 1 (14492.5) 1 (14193) 1 (3784)
50112750 12 wks post EDI 2 (4645.25) 2 (14340.5) 2 (1693.5)
50112763 May-09 3 (7211.0) 3 (9996) 3 (2529)
50112814 27 wks post EDI 2 (4881.25) 2 (5045.5) 2 (2699.5)
50115210 1 wks post EDI 1 (3611.5) 1 (10953) 1 (3559)
13 wks post EDI 1 (9113.0) 1 (9015) 1 (2775)
50115220 Sep-09 0 2 (5171.5) 2 (8813.0)
Oct-09 1 (6017.0) 1 (6893) 1 (1244)
50116970 12 wks post EDI 1 (9097.0) 1 (14520) 1 (3728)
30 wks post EDI 1 (13917.0) 1 (13521) 1 (3133)
50117060 Nov-09 2 (4918.0) 2 (6227.0) 2 (2829.5)
50117720 10 wks post EDI 2 (3081.75) 2 (8236.0) 2 (6514.0)
222-27v 10 wks post EDI 1 (8027.0) 1 (13273) 1 (2050)
222-2nq Oct-10 0 4 (15332.5) 4 (2392.5)
222-2qd 10 wks post EDI 1 (4913.5) 1 (9769) 1 (4210)
222-2rc 20 wks post EDI 4 (3952.5) 4 (6142.0) 4 (3579.0)
222-5te 11 wks post EDI 2 (4003.5) 2 (10580.0) 2 (4410.5)
222-69g 2 wks post EDI 2 (3856.75) 2 (2571.5) 2 (3513.0)
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Table A.2: (continued) NGS library information for each of the sequenced participants. For
individuals with an available estimated date of infection (EDI), sample dates are listed relative
to the EDI; for others (chronically infected), the dates are listed as month/year. For each patient,
the dual infection status is indicated: SI – superinfection, CI – coinfection. A successful
replicate was defined as having median sequenced region coverage of 500 or greater. There are
five dually infected individuals marked with (*): the DI status of these individuals was
originally determined using single genome sequencing and confirmed using NGS of a single
time-point [94].
(DI) PID Sample date Successful replicates (median coverage)
rt gag env
222-7w4 2 wks post EDI 4 (5509.25) 4 (7530.0) 4 (4896.5)
222-8eq 2 wks post EDI 1 (4340.5) 1 (6601) 1 (3288)
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Appendix B
IDEPI: rapid prediction of HIV-1 antibody
epitopes and other phenotypic features
from sequence data using a flexible
machine learning platform
B.1 Supplementary methods
B.1.1 Simulated data
We simulated the evolution of N = 241 HIV-1 protein envelope sequences subject to
a directional selective pressure applied to sites in an epitope using the HyPhy package [104]:
the reference HXB2 sequence was evolved along a phylogenetic tree representing the diversity
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of circulating HIV-1 group M strains (inferred from biological isolates), subject to an HIV-1
specific substitution model [91], with site-to-site substitution rate heterogeneity modeled by a
3-bin general discrete distribution [103]. The development of resistance to a particular simulated
epitope in a subset of sequences (defined as a set of positions in the genome and “escape” residue),
was modeled by accelerating the rate of amino-acid substitution towards the escape residue along
the terminal tree branch leading to a resistant sequence. For each replicate (100 replicates per set),
an epitope of desired complexity was generated (Table 4.1), and each simulated sequence was
assigned a phenotype as a deterministic function of its genotype. We also performed a simulation
where phenotypes were assigned to sequences randomly, in order to establish the degree to which
phylogenetic relatedness can drive spurious associations due to the non-independence of samples
[41].
B.1.2 Drug resistance
We labeled a sequence resistant to NVP if the measured fold change in IC50 was 5 or
greater. A feature was reported if it appeared in 3 or more out of 5 cross-validation replicates.
We investigated the complexity of the genotypic basis of resistance by a simple grid search (the
number of features was one of the following values: 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50,
60, 70, 80, 90, 100; see Figure 4.2A)
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B.1.3 Co-receptor usage/tropism
The number of features maximizing 5-fold cross-validation MCC was determined by
a simple grid search. In addition to cross-validation performance metrics, we compared the
performance of the IDEPI model to the methods considered by Dybowski et al [27] on an
independent validation dataset with 74 sequences.
B.1.4 Broadly neutralizing antibodies
IDEPI labeled sequences with IC50 of ≥ 20µg/mL for a given bNab as resistant, except
for the 10E8 bNab (which shows unusually low titers for the reference panel), where the threshold
was lowered to 5µg/mL. Because typical distributions of IC50 values are strongly bimodal (peaks
near 0 and maximum measured value of 50 µg/mL), classification performance was not unduly
sensitive to the choice of cutoff values; further, the mapping from IC50 to phenotype labels can be
specified as a run-time option, making the threshold trivially tunable. The number of features
maximizing 5-fold cross-validation MCC was determined by a simple grid search (as before, the
number of features was one of: 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100).
B.1.5 Computational resources and software versions
All experiments were performed with IDEPI v0.17, sklmrmr v0.2.0, scikit-learn v0.14.1,
scipy v0.12.0, numpy v1.7.1, BioPython v1.62, and Python v3.3.1 on a Penguin Computing Altus
server (dual 8-core AMD Opteron 6128) running CentOS 6.4.
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